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1.1 Integrating clinical informatics with genomics and mobile health enables p-
Health through advanced data analytics. The typical data analysis pipeline
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modeling, decision making, and action-taking. Data integration can be
achieved along this pipeline at the raw data level, feature level, and de-
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1.2 A overview of clinical informatics. In-clinic and out-of-clinic health in-
formation contribute to the primary data sources for clinical informatics.
Data from different sources are combined to form the feature representa-
tion of each patient, for later clinical endpoints such as clinical outcome
prediction, early prevention, and public health reporting. . . . . . . . . . . 5
1.3 An overview of genomic medicine. DNAs/RNAs are firstly extracted from
the patient’s blood, biopsy, or body fluid samples, and then genotyped by ei-
ther microarray or sequencing. The raw genomic data are further analyzed
with bioinformatics approaches to generate a list of genomic variants. AI-
based computational modeling is applied for disease-related genomic vari-
ants discovery with the guidance of current knowledge bases. The identi-
fied genomic biomarkers will be evaluated and validated by domain experts
and enrich the knowledge bases. Oncogenomics, pharmacogenomics, and
disease risk prediction are three major components of genomic medicine,
enabling disease prevention, diagnosis, personalized treatment, risk assess-
ment, and health management and monitoring. . . . . . . . . . . . . . . . . 7
1.4 An overview of medical imaging informatics. Medical imaging informat-
ics aims to enable quantitative and robust analysis of medical images by
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2.1 Summary of advanced data integration analytics. The multi-modal health
data can be integrated at the raw data level, feature level, and decision level.
At the raw data level, health data from different modalities and cohorts are
harmonized. Features from different data can be integrated by concatena-
tion, transformation, or deep learning methods at the feature level. At the
decision level, the outputs of multiple models are combined for decision
making and further action taking by the doctors. . . . . . . . . . . . . . . . 14
2.2 Two application scenarios for consensus and complementary principles.
A. For dependent modalities such as multi-omics, we can apply the con-
sensus principle for integration. B. For independent modalities such as
gene+environmental data, we can apply the complementary principle for
integration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3 Integrating independent multi-modal biomedical data with complementary
principle. We can apply modality-specific deep networks for each data
modality independently and then combine the hidden features learned for
each modality by concatenation. . . . . . . . . . . . . . . . . . . . . . . . 25
2.4 Venn diagram of the ADNI data. 220 patients had all the three data modal-
ities, 588 patients had SNP and EHR, 283 patients had imaging and EHR,
the remaining patients had only EHR data. . . . . . . . . . . . . . . . . . . 28
2.5 Deep Model for Data Integration Compared with Shallow Models of Data
Integration. a) Feature level integration on shallow models, where the fea-
tures are concatenated before passing into shallow models. b) Deep in-
termediate feature level integration where the original features are trans-
formed separatelyusing deep models prior to integration and prediction. c)
Decision level integration where voting is performed using decisions of in-
dividual classifiers. In this study, we comparee the performance of deep
intermediate level integration against shallow feature and decision levels
integrations for the prediction of Alzheimer’s stages. . . . . . . . . . . . . 29
2.6 Intermediate-Feature-Level Combination Deep Models for Multimodality
Data Integration for Clinical Decision Support. Data from diverse sources,
imaging, EHR and SNP are combined using novel deep architectures. 3D
convolutional neural network architectures used on 3D MR image regions
to obtain intermediate imaging features. Deep stacked denoising autoen-
coders are used to obtain intermediate EHR features. Deep stacked denois-
ing autoencoders are used obtain intermediate SNP features. The 3 types of
intermediate features are passed into a classification layer for classification
into Alzheimer’s stages (CN, MCI and AD). . . . . . . . . . . . . . . . . . 31
xii
2.7 Internal Cross Validation Results for Individual Data Modality to Predict
Alzheimer’s Stage a) Imaging Results: Deep learning prediction performs
better than shallow learning predictions b) EHR Results: Deep learning
outperforms shallow models kNN and SVM and is comparable to deci-
sion trees and random forests c) SNP Results: Deep learning outperforms
shallow models. The kNN, SVM , RF and decision trees are shallow mod-
els. ((kNN: k-Nearest Neighbors, SVM: Support Vector Machines, and RF:
Random Forests). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.8 Internal Cross Validation Results for Integration of Data Modalities to Pre-
dict Alzheimer’s Stage. a) Imaging + EHR + SNP: Deep learning pre-
diction performs better than shallow learning predictions. b) EHR + SNP:
Deep learning prediction performs better than shallow learning predictions.
c) Imaging + HER: Deep learning prediction performs better than shallow
learning predictions. d) Imaging + SNP: Shallow learning gave a better
prediction than deep learning due to small sample sizes. (kNN: k-Nearest
Neighbors, SVM: Support Vector Machines, RF: Random Forests, SM:
Shallow Models, and DL: Deep Learning). . . . . . . . . . . . . . . . . . . 34
3.1 The SEQC consortium developed and validated a guideline for selecting
RNA-seq pipelines for gene expression-based predictive modeling using
the SEQC-benchmark, SEQC-neuroblastoma, and TCGA-lung-adenocarcinoma
datasets. Phase-1 of the investigation developed the metrics that captured
the accuracy, precision, and reliability of RNA-seq pipelines (the blue box).
Using the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets,
Phase-2 of the investigation determined that RNA-seq pipeline metrics can
be used to select pipelines that result in better performance in terms of pre-
dicting cancer outcome (the pink box). . . . . . . . . . . . . . . . . . . . . 42
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3.2 The 278 RNA-seq pipelines applied to the SEQC-benchmark dataset dif-
fer in terms of gene expression accuracy, precision, and reliability. In each
heatmap, the rows are different settings for 13 aligners and the columns
are combinations of three quantification and seven normalization methods.
(a) Accuracy is defined as the deviation of pipeline-derived log ratios of
gene expression from the corresponding qPCR-based log ratios. Median
accuracy of all genes (i.e., 10,222 genes) is encoded as color, with red rep-
resenting the highest accuracy, or the lowest deviation from qPCR. (b) Pre-
cision is defined as the coefficient of variation (CoV) of gene expression
over replicate libraries. Median precision of all genes is encoded as color,
with red indicating the highest precision, or the lowest CoV. (c) Reliabil-
ity is defined as the intraclass (or intra-sample in our context) correlation
that quantifies how similar replicate libraries of a sample are to one another
using analysis of variance techniques. Median reliability of all genes is
encoded as color, with red representing the highest reliability, or the high-
est intraclass correlation. Refer to [119] for mathematical definitions of
accuracy, precision, and reliability in the context of RNA-seq pipelines. . . 43
3.3 Analysis of variance decomposes the overall variance in (a) median accu-
racy of all genes, (b) median precision of all genes, and (c) median relia-
bility of all genes into various factors considered, including five RNA-seq
pipeline components (i.e., mapping algorithm, mapping strategy, mapping
reporting, quantification, and normalization) and nine associated two-way
interactions. The statistical significance of each component’s or interac-
tion’s contribution is denoted by red asterisks, with ‘***’ indicating p-
values are smaller than 0.001, ‘**’ indicating p-values are smaller than
0.01, and ‘*’ indicating p-values are smaller than 0.05. . . . . . . . . . . . 44
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3.4 RNA-seq pipelines selected based on benchmark metrics (i.e., accuracy,
precision, and reliability) were informative for inferring the performance of
gene-expression-based prediction of disease outcome—(a) prediction per-
formance measured by the area under the receiver operating characteris-
tic curve (AUROC, or AUC) for the overall survival (OS) endpoint of the
SEQC-neuroblastoma (NB) dataset; (b) prediction performance measured
by the Matthews correlation coefficient (MCC) for the OS endpoint of the
SEQC-NB dataset; (c) prediction performance measured by the AUC for
the event-free survival (EFS) endpoint of the SEQC-NB dataset; (d) predic-
tion performance measured by the MCC for the EFS endpoint of the SEQC-
NB dataset; (e) prediction performance measured by the AUC for the sur-
vival endpoint of the TCGA-lung-adenocarcinoma (LUAD) dataset; and (f)
prediction performance measured by the MCC for the survival endpoint of
the TCGA-LUAD dataset. The red line in each panel shows the proba-
bility density of the prediction performance of good-performing RNA-seq
pipelines selected based on benchmark metrics; and the blue line demon-
strates that of poor-performing pipelines selected based on the same. Statis-
tical significance (i.e., p-values) was determined using the one-sided Wilcoxon
rank-sum test. Panels (a), (b), and (d) show a statistically significant dif-
ference (p¡0.05) between the two groups (i.e., the prediction performance
of good-performing pipelines vs. that of poor-performing pipelines). The
good-performing (Top 10%) and poor-performing pipelines (Bottom 10%)
were determined based on the average rank of each RNA-seq pipeline over
all benchmark metrics of both all and low-expressing genes. . . . . . . . . 50
3.5 The RNA-seq pipeline selection guide was validated by assessing the abil-
ity of pipelines to stratify patients based on Kaplan-Meier survival anal-
ysis. For each pipeline, patients were grouped by predictive labels (i.e.,
high risk vs. low risk), and two Kaplan-Meier curves were plotted. The
two-tailed log-rank test was used to determine the statistical significance
of the separation between the two curves. For good-performing pipelines
selected based on benchmark metrics, the success rates of patient stratifi-
cation (i.e., predictive labels led to a statistically significant separation of
Kaplan-Meier curves) were higher. For example, the success rates of the
[GSNAP (un-spliced, single-hit) + Cufflinks + Median] pipeline were 93%,
70%, and 67% for the SEQC-NB OS, SEQC-NB-EFS, and TCGA-LUAD-
Survival endpoints, respectively. Panels (a) to (c) demonstrate the most
statistically significant separation of the two Kaplan-Meier curves for each
endpoint. In contrast, poor-performing pipelines led to lower success rates
of patient stratification. For instance, the success rates of the [BWA (un-
spliced, single-hit) + RSEM + RLE] pipeline were 33%, 30%, and 33% for
the SEQC-NB OS, SEQC-NB-EFS, and TCGA-LUAD-Survival endpoints,
respectively. Panels (d) to (f) demonstrate the least statistically significant
separation of the two Kaplan-Meier curves for each endpoint. . . . . . . . . 52
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3.6 The resources provided by this study (i.e., the 278 RNA-seq pipelines, the
benchmark metrics, and the SEQC-benchmark datasets) can serve as guide-
lines for biological and clinical researchers as well as for bioinformaticians
and biotechnologists. (a) Depending on the gene expression application,
the three metrics (i.e., accuracy, precision, and reliability) may be used
to choose a pipeline. We have associated each metric with an RNA-seq
application and listed the top-performing pipelines for each metric. The
red-highlighted component in each listed RNA-seq pipeline indicates com-
ponents that frequently occur among the top-performing pipelines for each
metric. (b) Biological or clinical researchers who want to analyze Illu-
mina RNA-seq data (or data from similar platforms with short, fixed-length
reads) can choose an existing RNA-seq pipeline using the provided table
of 278 pipelines ranked by accuracy, precision, or reliability. Bioinfor-
maticians that are developing a new RNA-seq pipeline for Illumina data
(or data from similar platforms) can use the SEQC-benchmark datasets and
benchmark metrics to evaluate the new pipeline and assess its performance
relative to the 278 pipelines. Bioinformaticians or biotechnologists that are
developing new RNA-seq protocols can first sequence the same RNA mix-
ture samples (i.e., samples A, B, C, and D), and then evaluate associated
data analysis pipelines using the qPCR benchmark dataset and the bench-
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3.7 Simulation two-view data from MNIST database. A. Pipeline for simula-
tion of two-view data from the MNIST database. B. Simulated dataset S1
with random erasing noise. C. Simulated dataset S2 with Gaussian noise. . . 61
3.8 Overall pipeline for survival analysis. We obtain multi-omics data (i.e.,
gene expression, DNA methylation, miRNA expression, and copy number
variation) for breast cancer patients from the TCGA-BRCA database. The
multi-omics data are preprocessed and normalized to a range of 0 to 1. We
then apply four-fold cross-validation and split the data into a training set
(60%), validation set (15%), and testing set (25%) in each fold. We train
the feature selection or dimension reduction step and the survival networks
using the training set and apply them to the validation set for parameter
selection and the testing set for performance reporting. . . . . . . . . . . . 63
3.9 Single-omics data survival analysis network. The input data x is repre-
sented with an encoder q(x) into hidden feature z and then constructed
with a decoder p(x). We then feed the hidden feature z into a task-specific
network such as multi-class classification or survival analysis. . . . . . . . . 65
3.10 Multi-omics data integration with concatenation autoencoder (ConcatAE).
The hidden features of each data modality are concatenated before feeding
into the task-specific network. . . . . . . . . . . . . . . . . . . . . . . . . 67
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3.11 Multi-omics data integration with cross-modality autoencoder (CrossAE).
For hidden features of each data modality, they are used to reconstruct input
features of both the original modality and other modalities. The hidden
features of various modalities are element-wise averaged before feeding
into the task-specific network. . . . . . . . . . . . . . . . . . . . . . . . . 68
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SUMMARY
With the advancement of biotechnologies such as high-throughput sequencing, a mas-
sive amount of multi-modal biomedical data has been generated at an unprecedented speed
and volume every year. However, extracting information and obtaining knowledge from
these multi-modal biomedical data remains a major challenge in research and clinical ap-
plications. Multiple computational approaches were proposed for multi-modal biomedical
data integration, aiming to combine data from disparate sources to increase the value of
data and improve data integrity. Multi-modal biomedical data were hypothesized to con-
tain both dependent and independent information based on multi-view learning’s consensus
and complementary principles. For modalities with independent information or few con-
nections (e.g., genetic factors vs. environmental factors), the complementary principle was
utilized to integrate data from different modalities by concatenating the hidden features
learned with independent feature representation. Thus, the unique information in each data
modality can jointly contribute to the final decision. The proposed framework has been
applied to integrate electronic health records (EHRs) with MRI Imaging and single nu-
cleotide polymorphisms (SNPs) data for improved prediction of Alzheimer’s Disease. For
modalities with dependent information (e.g., multi-omics data), the complex interactions
between modalities were modeled implicitly with the consensus principle. As features from
dependent modalities are connected by either association or causal relationships, they can
be integrated by the consensus principle to improve the robustness and eliminate inconsis-
tencies. A consensus regularization was achieved by requiring the features encoded from
various modalities of the same subject to consent in a common feature space. The proposed
frameworks have been applied to integrate multi-omics data (e.g., mRNA expression, DNA
methylation, miRNA expression, and copy number variations) for improved breast cancer
overall survival prediction. Generalized data integration models such as autoencoder-based
semi-supervised learning frameworks have also been explored to improve computer-aided
xxi
decision support performance. By integrating multi-modal biomedical data with the pro-
posed frameworks, the healthcare quality is expected to be improved with a more compre-




Delivering predictive, precise, participatory, preventive, and personalized health, abbrevi-
ated as p-Health, is the primary goal of future healthcare systems that can significantly
improve care quality while reducing cost. To accomplish this goal, researchers are de-
veloping translational data analytics pipelines to jointly assess and validate the in-clinic
Electronic Health Records (EHRs), out-of-clinic Personal Health Records (PHRs) [1], and
high-throughput genomic data. A typical pipeline consists of six steps: data collection,
data quality control, feature extraction, knowledge modeling, decision making, and action-
taking. However, how to integrate multi-modal biomedical data in an efficient way remains
a major challenge. This chapter will review the challenges and opportunities in data inte-
gration analytics at three levels (i.e., raw data, feature, and decision levels) from clinical
informatics to genomics for p-Health as shown in Figure 1.1.
Clinical informatics was first introduced in the 1950s, when the US National Bureau
of Standards, the US Air Force used digital computers to develop expert systems (such as
MYCIN and Internist-I [2]) and computerized medical records management system. In
1959, Ledley et al. [3] published in Science that discussed the idea of using computational
reasoning to aid medical diagnostic processes for the first time. EHR systems improve the
communication among physicians, providers, and patients, the quality of clinical decisions,
and the delivery of cares significantly in hospital routine practices [4]. However, due to the
low EHR adoption rate, clinical informatics progress was slow. In 2008, the American Hos-
pital Association (AHA) Annual Survey reported that only 13.4% of the non-Federal acute
care hospitals in the US had adopted basic or comprehensive EHR systems and only 1.6%
have an EHR system with clinical decision support [5]. With the new policy “the Health
Information Technology for Economic and Clinical Health (HITECH) Act 2009”, in 2015,
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the EHR system adoption rate has increased to about 80% in the US, and 34.4% of these
hospitals have EHR systems with clinical decision support [5]. Recently, the advancement
of low-cost sensors embedded in mobile phones or wearable devices has enabled out-of-
clinic care captured in PHRs that expand EHRs. The continuous monitoring of a person’s
daily physiology and communication enables personalized preventive and predictive health
by disease early warnings and participatory patient education that bridges the gap between
in-clinic and out-of-clinic care for p-Health. We loosely use EHRs to cover both traditional
EHR and PHR for clinical informatics within the context of this dissertation.
After Human Genome Project was finished in 2001 [6], using genomics to customize
clinical care becomes possible. Genomics focuses on discovering the structure and func-
tion of genomes, which is the complete set of DNA in an organism. Based on the Na-
tional Human Genome Research Institute (NHGRI) definition, “Genomic Medicine” is an
emerging medical discipline that uses genomic information of an individual for his/her
clinical care and health outcomes. The NHGRI “Genomics” covers the study of direct in-
formation about DNA or RNA, excluding the study of downstream derived products (e.g.,
proteomics, metabolomics). DNA sequences can capture genomic variations at single nu-
cleotide level like single nucleotide polymorphisms (SNPs) [7] or chromosome level like
structure variations (SVs) [8]. RNA sequences contain genomic variations as gene expres-
sions or alternative splicing events [9]. Because human diseases are complex interactions
between genotypes and environment [10], incorporating molecular level information such
as genetic variations is essential for precision medicine to speed up the accomplishment
of p-Health. The unique genetic information of individuals can reveal the disease status
and responses to treatments (e.g., more than 80% of rare diseases are related to genetic
mutations, and genomics can play an important role in the diagnosis [11]). The genomic
variations detected in DNA or RNA sequences are genotypes, a complement to disease phe-
notypes in genomic medicine. With the development of high-throughput next-generation
sequencing (NGS) technologies, genomic data such as the whole genome of an individual
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can be sequenced for as little as $1,000 in a few days [12].
Integrating “clinical informatics” and “genomic medicine” presents us with challenges
including data harmonization, data quality control, and advanced data analytics to build an
integrated intelligent clinical decision support system for p-Health (Figure 1.1). To solve
these challenges, we can perform data integration at three different levels of the six-step
data-analytic pipeline: raw data level, feature level, and decision level (Figure 1.1).
1.1 Clinical Informatics
Clinical informatics uses data analytics to gain new insight from individual and population
health records and to improve clinical decision making by combining data-derived knowl-
edge and domain expert knowledge (Figure 1.2). Typical data sources include conventional
personal health records and public health data.
Conventional individual health records contain various data types, from structured billing
codes to unstructured clinical notes, which is the first challenge in clinical informatics.
Throughout the hospital stay of patients, administrative information (e.g., demographics,
gender information, and diagnostic codes, for billing and public health reporting purposes),
auxiliary clinical data (e.g., lab tests, medical and radiological imaging, medication, genet-
ics, continuous physiological data such as bedside monitoring data in intensive care units),
and unstructured clinical notes record comprehensive information about patients’ clinical
status and outpatient care information. The public health data set is more abstract and often
contains aggregated statistics of diseases in geographical regions and times. For example,
the national center for health statistics (NCHS) collects 2.6 million death certificates each
year that record demographics, causes of death of the US population. Recently, billions
of mobile phones and wearable sensors (e.g., FitBit) and behavior imaging enable routine
health monitoring in outpatient care. PHRs collect data from these applications and provide
a more personalized evaluation of patients. Within the context of this dissertation, we use






































Feedback for Model Improvement
Figure 1.1: Integrating clinical informatics with genomics and mobile health enables p-
Health through advanced data analytics. The typical data analysis pipeline consists of data
collection, quality control, feature extraction, knowledge modeling, decision making, and
action-taking. Data integration can be achieved along this pipeline at the raw data level,




























Figure 1.2: A overview of clinical informatics. In-clinic and out-of-clinic health informa-
tion contribute to the primary data sources for clinical informatics. Data from different
sources are combined to form the feature representation of each patient, for later clinical
endpoints such as clinical outcome prediction, early prevention, and public health report-
ing.
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with EHRs to become “extended” EHRs.
Other data sources that attribute to health include ontology, such as Unified Medical
Language System (UMLS), SNOMED CT [13]. Physicians and clinical researchers use
nodes to represent medical concepts and edges between nodes to encode the relationships
between concepts such as what diseases can lead to specific symptoms, what medications
can help alleviate certain symptoms.
Analyzing these data has benefits to both population and individual care for p-Health.
At the population care level, health policymakers are interested in understanding epidemics
from a statistical point of view across spatial and temporal dimensions [14]. Aggregated
EHRs help explore the evolution and spreading of diseases for resource allocation, which
may be used to predict and prevent the outbreak of epidemics. Death certificates may con-
tain the causes of deaths for each death case and help understand the diseases spread in
the nation. At the individual care level, diagnosing patients’ conditions and deciding prog-
nosis are two crucial steps. Clinical informatics can provide decision support for in-clinic
physicians and care providers [15], where clinical outcome (e.g., hospital readmission and
mortality) prediction helps prevent adverse in-clinic clinical events. Mobile sensor data
prediction gives early warnings of medical conditions and provides physicians with out-
of-clinic participatory health. Besides prediction, grouping similar patients’ record [16]
and simulation [17] can suggest reference treatment options to assist in the clinical action-
taking.
Due to privacy and other health regulatory issues, only a limited number of datasets
are publicly available. Comprehensive data sets may be obtained through research col-
laboration with specific clinical institutions. As the data available are only multiple types
of observations, to truly achieve personalized and precise health [17], it is critical to ex-
panding to genome medicine[18], which is presented in the next section. However, clinical

































Figure 1.3: An overview of genomic medicine. DNAs/RNAs are firstly extracted from the
patient’s blood, biopsy, or body fluid samples, and then genotyped by either microarray or
sequencing. The raw genomic data are further analyzed with bioinformatics approaches
to generate a list of genomic variants. AI-based computational modeling is applied for
disease-related genomic variants discovery with the guidance of current knowledge bases.
The identified genomic biomarkers will be evaluated and validated by domain experts and
enrich the knowledge bases. Oncogenomics, pharmacogenomics, and disease risk predic-
tion are three major components of genomic medicine, enabling disease prevention, diag-
nosis, personalized treatment, risk assessment, and health management and monitoring.
1.2 Genomic Medicine
Genomic medicine aims at utilizing an individual’s genomic information for preventing, di-
agnosing, and treating diseases in clinical care and p-Health (Figure 1.3). Human diseases
are results of complex interactions of genotypes and environmental factors [10]. Person-
alized information embedded in genomics can help physicians predict disease risk factors
and patients’ responses to treatments. For example, because specific inherited mutations in
tumor suppressor genes BRCA1 and BRCA2 increase the risk of female breast and ovarian
cancers [19], genetic tests of BRCA1 and BRCA2 mutations can prevent, early-diagnose,
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and treat breast and ovarian cancers. Genomic medicine has been mainly applied to three
areas: oncogenomics, pharmacogenomics, and disease risk prediction. Oncogenomics and
pharmacogenomics are the two most studied applications of personalized genomics [20].
Disease risk prediction is especially beneficial for those diseases with genetic markers of
high clinical impacts.
Oncogenomics is a study for cancer–related genes. As a well-recognized genetic dis-
ease [21], various cancers have been studied extensively with genomics to identify cancer-
related genetic variations for personalized diagnosis and treatment [22]. For example,
Nguyen et al. have applied personal genomics to relate the outcome after breast-conserving
therapy with breast cancer subtypes [23]. Zheng et al. have associated genetic variations
with prostate cancer [24]. Pharmacogenomics is the study of how a person’s genome af-
fects his/her response to drugs (i.e., the relationship between genetic variations and drug
responses). It can guide the physicians to choose the optimal medicine for patients based
on their genetic variations to minimize adverse drug reactions and to maximize effective-
ness [20] for personalized care. For example, the chemotherapeutic agent Vemurafenib
targets melanoma with BRAF V600E mutation, where the efficacy and adverse events have
been evaluated [25]. Disease risks vary with the patient’s genetic variations. For exam-
ple, 80% of rare diseases have genetic origins, which makes personalized genomics es-
sential for early screening, diagnosis, and individualized treatment for rare diseases [11].
Multiple rare diseases have genetic biomarkers with sufficiently high clinical impact, and
more are discovered each year. Combining genetic biomarkers using genome-wide asso-
ciation studies (GWAS) with environmental factors, the risk factors of some diseases can
be thoroughly assessed for earlier intervention and better treatment. Various databases and
projects have been established for genetic variants discovery for general purposes, specific
diseases, and specific populations. The first group of projects aims to discover genetic
variants and to understand the functions. To identify the common genetic variations and
to discover novel ones in the human genome, 1000 Genomes Project [26], followed by
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10,000 human genomes project [27], sequenced a large number of human genomes. These
projects provide a base for the clinical use of genetic variations. The encyclopedia of DNA
elements project (ENCODE) [28] aims to discover the functional elements in the human
genome to make sense of genomic data. UK Biobank [29] connects genetic variants with a
wide range of diseases and outcomes by providing EHR (with imaging) and genomic data,
which is a perfect resource for integrated data analytics.
The second group of projects aims to understand and treat specific diseases. These
projects include the cancer genome atlas project (TCGA) [30], Alzheimer’s Disease neu-
roimaging initiative (ADNI) [31], and Parkinson’s progression markers initiative (PPMI)
[32]. TCGA project focuses on utilizing cancer genomics to improve the understand-
ing, prevention, diagnosis, and treatment of various cancers. Similarly, ADNI and PPMI
projects are developed for two of the most prevalent neurodegenerative diseases, Alzheimer’s
disease and Parkinson’s disease, respectively. These disease-oriented databases collect
multi-omics data, clinical information (EHR), and medical imaging data (magnetic res-
onance imaging (MRI), positron emission tomography (PET), and pathological images)
for specific diseases. The multi-modal data collected by these databases enable data inte-
gration for a better understanding of the disease.
The third group of projects aims to stratify medicine for specific populations. One ex-
ample is the minority health genomic and translational research bio-repository database
(MH-GRID) [33]. Motivated by the fact that high blood pressure affects African Ameri-
cans more than other racial groups, MH-GRID contains data collected from over a thousand
African Americans across the US. Besides genetic data, MH-GRID also collects health-
related information such as diet, sleep, body mass index, stress, access to healthy food and
parks. Besides publicly available databases and projects, various bioinformatics tools and
pipelines have also been developed for DNA and RNA analysis in personalized genomic
medicine. DNAs and RNAs can be first sequenced by next-generation sequencing (NGS)























Figure 1.4: An overview of medical imaging informatics. Medical imaging informatics
aims to enable quantitative and robust analysis of medical images by computational meth-
ods.
method’s chain-termination, NGS techniques parallelize the sequencing process and pro-
duce millions of sequences concurrently [34] by using sequencing-by-synthesis, and have
significantly lowered the cost of DNA sequencing compared to the Sanger method [34].
The first step of genomic data analysis is sequencing data quality control to remove poten-
tial artifacts and low-quality reads. The sequenced short reads passed quality control are
then aligned to the reference genome. The aligned reads are further analyzed to identify
various genetic variations like SNPs and copy number variations (CNVs). Based on the
NHGRI genomic definition, genetic variations at the transcription level can be character-
ized by RNA-seq to obtain gene expression, alternative splicing, and gene fusion. That is,
RNA sequencing (RNA-seq) reads are first aligned to the genome (spliced alignment) or
transcriptome (un-spliced alignment) and are then quantified and normalized to get gene
expression levels. RNA-seq can capture major transcription-level regulation events like
alternative splicing [9]. These innovations in sequencing technologies and bioinformatics
pipelines pave the way for personalized genomic medicine.
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1.3 Medical Imaging Informatics
Medical imaging informatics aims to improve imaging-based diagnosis’s efficiency and
accuracy through digital imaging processing and machine learning (Figure 1.4). A typi-
cal computer-aided diagnosis (CAD) system for medical imaging analysis consists of four
major components: 1) image quality control, 2) feature extraction at the pixel, object, and
semantic levels, 3) predictive modeling using imaging features, and 4) model visualization
for interactive discovery [35].
Image quality control is an essential step for medical imaging analysis. Typical qual-
ity issues for medical images include batch effects and artifacts. For example, the batch
effects for pathological images are caused by different clinical sites with various platforms
and slide preparation protocols. Besides batch effects, pathological images also suffer from
artifacts, including tissue folds, blurred regions, pen marks, and shadows. The batch effects
and image artifacts have unpredictable effects on image segmentation, classification, and
other quantitative image analysis tasks. Researchers have developed multiple techniques,
including color normalization, scale normalization, and blur detection, to eliminate or cor-
rect the batch-effect and image artifacts of WSIs.
Feature extraction is another essential step to analyze medical images quantitatively.
Conventional digital imaging processing techniques extract features from pathological im-
ages at pixel and object levels to capture the morphological properties [36]. Pixel-level
feature extraction identifies the properties of color and texture for all image pixels. Color
features are typically expressed with the color spread, prominence, and co-occurrence us-
ing statistics and frequencies of color histograms in different color spaces. Texture features
quantify image sharpness, contrast, changes in intensity, and discontinuities or edges by
measuring properties from gray-level intensity profiles. Object-level feature extraction re-
quires the segmentation of cellular structures and captures the shape, texture, and spatial
distribution of cellular structures in a WSI. Besides the features extracted from WSI, re-
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searchers also proposed to integrate the pathological features with clinical features and
genomic features for improved diagnosis [37].
However, the conventional feature extraction relies heavily on hand-crafted features,
which limits the generalizability of the features. With the development of deep learning,
the human-designed feature extraction has been replaced by feature representation with
deep neural networks. For imaging data, the most popular feature representation network
is the convolutional neural network (ConvNets). Deep ConvNets can learn efficient feature
representation from a large amount of training data. By combining ConvNets with fully
connected (FC) layers and a softmax layer for classification, the deep networks can be
trained end-to-end and thus can learn both feature representation and classification from the
training data. With the success of deep learning in natural images, deep neural networks
like ConvNets have been applied to medical images including MRI (brain tumor [38]),
CT (lung nodule [39]), and WSI (breast cancer [40], lung cancer [41], glioma [42], heart
rejection [43], etc.).
With multi-modal biomedical data discussed above, how to combine various data modal-
ities of the same patient becomes a practical yet challenging task. Valid data integration
should provide a more comprehensive evaluation of the patient and enable personalized
diagnosis and treatment. In the following chapters, we will discuss the practical challenges
for data integration and present the proposed data integration methods.
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CHAPTER 2
INTEGRATING MULTI-MODAL BIOMEDICAL DATA WITH FEATURE
CONCATENATION
2.1 State-of-the-art biomedical data integration
Data integration aims to use multiple sources of information to better understand a sys-
tem (Figure 1.2). Wong reviewed requirements and solutions to the data integration and
warehouse at the raw data access level in biomedicine in EnsEMBL, GenoMax, and SRS
[44]. Goble et al. introduced “a loose federation of bio-nations” to handle biomedical data
sources’ heterogeneity and the ontology in data integration [45]. More recently, Gomez-
Cabrero et al. described how to deal with the diversity of existing omics data types and
formats of large datasets to obtain new insights [46]. They have applied dynamic Bayesian
networks, self-organizing maps, and network inference methods over popular data sources
such as the 1000 Genomes Project, ENCODE, TCGA, and ImmGen. Ritchie et al. re-
viewed the -omic data integration by comparing meta-dimensional and multi-stage analysis
[47]. Based on the current works for biomedical data integration, we identify the following
four challenges for integrating EHRs and genomic data:
The first challenge is data collection and harmonization. New technologies, such as
mobile sensors and DNA sequencing, all require modality-specific techniques to be stored,
visualized, and analyzed by computing devices. Genomic technologies are emerging every
year, ranging from microarray to third-generation sequencing, making genomic data het-
erogeneous with various formats and standards. Then NGS have different platforms such
as Illumina, 454 sequencing, or SOLiD sequencing, leading to more variations. The devel-
opment of third-generation sequencing by Pacific Biosciences [48] with much longer read
length will add further variants to genomic data. Validating the data generated by these var-
13
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Figure 2.1: Summary of advanced data integration analytics. The multi-modal health data
can be integrated at the raw data level, feature level, and decision level. At the raw data
level, health data from different modalities and cohorts are harmonized. Features from
different data can be integrated by concatenation, transformation, or deep learning methods
at the feature level. At the decision level, the outputs of multiple models are combined for
decision making and further action taking by the doctors.
ious technologies is challenging. How to harmonize different types of data and databases is
also challenging. In clinical informatics, there are 186 commercial EHR system vendors in
the U.S. Market, with Epic, Cerner, and MEDITECH being the top three with the highest
market shares. Each of them has its specific data standard and format. As a result, multi-
ple clinical institutions with different EHR vendors cannot exchange information directly
[49]. The international standard body, Health Level Seven International (HL7) [50], has
put a collaborative effort to develop a new EHR standard FHIR (Fast Healthcare Interop-
erability Resources), and its extensions SMART-on-FHIR to have data from different EHR
interoperable. In genomic medicine, currently, FHIR enables the incorporation of genomic
variations into EHRs. One example of establishing standards and APIs for genomic data
storing, sharing, and clinical applications is SMART on FHIR Genomics [51]. Thus, FHIR
app development presents challenges and opportunities.
The second challenge is data quality. In clinical informatics, EHR data can be unstruc-
tured and noisy with issues such as high percentages of missing values, errors, invalid data,
and outliers. Thus, data quality control processes, such as missing data imputation, data
conflict resolution, and data transformation, are needed. In genomic medicine, the DNA
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sequencing quality is affected by sample contaminations and sequencing errors. Thus,
numerous new bioinformatics approaches (e.g., FastQC) are developed to improve the se-
quencing quality before downstream analysis. In addition, to establish unified standards
for genomic data processing for reliable clinical applications, the US Food and Drug Ad-
ministration (FDA) coordinates the microarray quality control (MAQC) project [52] and
the sequencing quality control (SEQC) project [53] for a comprehensive assessment of
microarray and RNA-seq respectively.
The third challenge is to develop advanced data analytics to extract knowledge from
EHR and genomic data. In clinical informatics, feature engineering constructs a meaning-
ful set of representations for patients, including medications, lab tests, and procedures. The
conventional analytics rely on hand-crafted features or input from domain experts, which
are very limited in representation power. The new opportunities are on deep learning to
find representations from extensive data. In genomic medicine, the “curse of dimension-
ality” (i.e., the feature dimension is significantly larger than the patient sample size) is a
well-known challenge. For example, genome sequencing generates millions of genomic
variations such as SNPs, CNVs, gene expression levels, and alternative splicing events for
each sample. The sample size of the study may be several hundred. Directly applying
traditional data analysis will result in ill-conditioned feature matrixes. One solution is to
filter out irrelevant variants using feature selection in either a supervised or unsupervised
fashion. Lack of interpretability is another major challenge for EHR and genomic data ana-
lytics. Predictive models built on EHR data have shown potential in predicting the hospital
length of stay and readmission probability. However, deploying them in daily hospital prac-
tice is challenging because physicians cannot fully trust the model prediction. Most models
only provide a final prediction without a clear explanation of patients’ conditions lead to
the prediction. Making sense of genomic data is also a bottleneck for translating genomic
discoveries into clinical practice [54]. Current data-driven approaches are mostly based on
mathematical models, statistical tests, and computational methods. Lack of biological and
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clinical interpretation weakens the clinical impact of the novel genetic biomarkers discov-
ered. Experimental validation is essential for translating discoveries from data mining into
biological knowledge and further clinical care applications.
The fourth challenge concerns how to transfer knowledge to actionable decision mak-
ing. Artificial intelligence (AI) started in the 1950s and has undergone the paradigm shift
from symbolic logical reasoning to machine learning [55], including the recent success of
deep learning [56] in automatic representation learning. Deep learning has the potential
to provide highly accurate predictive modeling, and deep reinforcement learning shows
significant breakthroughs in playing video games, dialogue systems, and other tasks. How-
ever, a major challenge for computation decision making in clinical informatics is that it
is unethical to test different options and practically almost impossible to test two treatment
options in one individual. We may use historical data to simulate the effect of each ac-
tion applied to an individual, termed as counterfactual inference in the literature. However,
to ultimately address the problem, we need to understand the causal relationship between
medical events, treatment options, and diseases, for causality beyond correlation studies.
With these challenges presented, numerous works have been performed on multi-modal
biomedical data integration. This section reviews state-of-the-art data integration analytics
at the raw data level, feature level, and decision level to enable p-Health.
2.1.1 Raw Data Level Integration
Raw-data level integration happens in the data collection and storage stage, where dif-
ferent modalities of data are collected from different institutions and times for the same
disease. The multi-modal data from more patients can enable machine learning algorithms
to achieve better predictive models [57]. However, several challenges are also associated
with raw data integration.
The main challenge is that different institutes may use different EHR vendors with dif-
ferent formats. Existing standards such as Health Level Seven International (HL7) and
16
Clinical Document Architecture (CDA) [50] cannot support the interexchange of data from
different EHRs automatically for decision support systems. In contrast, manual data con-
version case-by-case is both time-consuming and prone to errors. Besides, ensuring privacy
and security in the raw data integration is also crucial [58]. To harmonize the data, HL7’s
has been developing Fast Healthcare Interoperability Resources (FHIR). FHIR is a new
emerging standard that uses a resource-centric approach (as opposed to document-centric).
FHIR specifies data elements into standardized healthcare data models and a set of applica-
tion programming interfaces (APIs) for interacting and modifying these data models [59].
Thus, data resources can exist as online services rather than static files so that applications
can read and write these resources in real-time. SMART-on-FHIR apps are based on FHIR
but work outside of the constraints by many stakeholders’ existing technical and security
infrastructures. Thus, raw data level integration opportunities include extending FHIR Re-
sources, implementing RESTful APIs, and SMART-on-FHIR apps to facilitate the raw data
integration process. For example, the applications include death reporting, health record
vendor translator, and mobile health apps [60]. Another example is the SMART on FHIR
Genomics for establishing standards and APIs for genomic data storing, sharing, and clin-
ical applications [51].
2.1.2 Feature Level Integration
The next step in the data analytics pipeline following data collection and quality con-
trol is feature extraction, and feature level integration includes both concatenation-based
and model-based methods. Directly concatenating raw features to integrate different data
modalities can introduce thousands of features. However, the challenges for integrating
EHRs and genomics features at the raw feature-level are that the information represented
by feature vectors may have varying representation power and noise. The computational
challenges introduced by adding features together may lead to model under-fitting or non-
convergence. Thus feature selection, such as L1 norm feature selection [61] and minimum-
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redundancy maximum-relevancy (mRMR) feature selection [62], is needed.
Model-based feature integration often adopts an encoder-decoder framework to com-
bine features from different modalities. For each modality, modality-specific encoders can
map features of every data modality to a joint feature embedding space first. Features
combined in the joint space will go through a single decoder for final reporting. Various
machine learning algorithms have been researched to accomplish model-based integration.
Multiple kernel learning (MKL) [63] learns a kernel transformation for each modality and
then combines all kernel transformations with a weighted linear average. Canonical cor-
relation analysis (CCA) [64] finds a new linear feature space, in which features from all
modalities has maximum correlation when projected onto the new space. Probabilistic
graphical model (PGM) [65] treats each feature as a random variable and perform statis-
tical inference to obtain an integrated feature, which is also represented in the form of
latent variables. These techniques are effective in several applications. However, the dis-
appearance of individual modality’s feature learning and feature integration may result in a
meaningless feature representation.
An emerging advanced AI method in feature-level integration is deep learning that can
combine feature extraction and prediction, learning a meaningful representation for high
accuracy in the given task [56]. Multi-modal deep learning [66] is an early work using the
restricted Boltzmann machine, while CCA is also extended with deep feedforward network
in [67] for feature-level integration. In clinical research, the multi-modal analysis using
deep learning is shown to improve model accuracy in medical imaging analysis [68].
The opportunities in advanced AI-based feature integration include constructing differ-
entiable encoders and the interpretation of integrated features and predictive models, espe-
cially deep learning models. Differentiable encoders can extract features from multi-modal
data (e.g., EHRs and genomic data) and train the whole pipeline with back propagation. On
feature interpretation, despite the progress in building highly accurate predictive models,
physicians will not trust black-box algorithms if they cannot understand what the features
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contribute to the final prediction and how they can link features to the original physiological
meaning. Perturbation analysis [69], influence functions [70], and visualization of neural
network outputs are some pioneering work for model interpretation. Identifying important
raw features that contribute to the final prediction or similar patients from historical data
are two directions that may help us understand the behavior of current models.
2.1.3 Decision Level Integration
Decision level integration first generates multiple base models using each data modality
independently as the training sets and then generates a final model by combining individual
models trained in the first step.
The challenges of decision level integration are the construction of accurate base deci-
sion models and the combination of base models that can prevent model overfitting while
adding more parameters.
The conventional decision-level combination uses simple majority, the weighted ma-
jority [71] (to predict protein fold recognition [72]), and ensemble learning. Ensemble
learning designs special weighting methods to addresses the overfitting by adjusting base
models with the resampled training set (bagging [73]), sequentially increasing weights of
misclassified training data (boosting [74]). For example, the random forest classifier makes
decisions based on the multiple decision trees it constructed from the resampled training
set; graphical-model-based approaches such as Bayesian networks combines multi-omics
data to better understand glioblastoma and breast cancer [75, 76]
In advanced AI methods for decision level integration, there exist three opportunities:
construction of base models, increasing interaction between different data modalities, and
reducing the gap between the decision and clinical action. First, designing accurate base
models is critical for final predictive accuracy. For example, in the majority voting scheme,
we need to choose one or more base models for each data modality from different models,
including decision tree, k nearest neighbors (kNN), support vector machine, logistic regres-
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sion, and neural network. For each base model, there are also multiple parameters to be
tuned. The selection of base models and parameter tuning can be tedious and also prone to
overfitting, especially for small sample sizes, so inventing efficient hyper-parameter tuning
algorithms such as Bayesian optimization can be an interesting direction.
Second, decision-level integration allows independent analysis of each data set, while
the integration at this upper level also limits the possible interactions among different data
modalities. Using the knowledge and decision from a resource-rich modality to assist de-
cision making in another modality is a challenging but rewarding task. For example, we
often only have limited data samples (patients’ data). However, we have a large collection
of biomedical domain knowledge, documented as research papers or medical ontologies.
Transferring decision from such knowledge or retrieving such knowledge for decision mak-
ing [77] can be helpful for physicians.
Third, bridging the huge gap in the decision-level integration can improve the final
clinical action-taking. After we design accurate predictive models with these integration
methods, suggesting viable actions (medications and procedures) for physicians remains a
challenge. Because even though randomized trials are widely used in drug and clinical tri-
als to determine the effect of new technology, in daily practice, physicians can only resort
to observational study for such evaluations [78]. To solve the problem, we need to under-
stand the causal relationship between genomic data, medical conditions, and treatment to
suggest and evaluate more reasonable actions. However, causal inference modeling is a
huge topic in biomedical big data analytics on its own, and we will not discuss it further in
this dissertation.
2.2 Multi-modal data integration by consensus and complementary principles
The advancement of biomedical techniques such as next-generation sequencing (NGS)
and wearable devices have generated high-throughput multi-modality data enabling a more
comprehensive view of the patients for personalized and precision care. Besides lab tests
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and medical imaging, physicians can order genetic tests to obtain patient genomics infor-
mation to make more accurate diagnoses and decisions. However, how to utilize these
multi-modal data remains a major challenge for both researchers and clinicians.
Multi-modal data analysis, including feature selection and predictive modeling, is more
complex than single-modality analysis due to the cross-modality information. There are
three ways to address this: to consider the cross-modality interaction and identify correlated
features among modalities in feature selection stage [79]; to integrate the multi-modality
information at the intermediate feature stage [80, 81, 82]; or to integrate at the decision
stage [83]. Although substantial progress has been made in this area, modeling the inter-
actions among modalities and getting rid of redundant or irrelevant information remains
extremely challenging.
2.2.1 Multi-view/ Multi-modal Learning
Data integration algorithm investigates how to combine multi-modal features of the same
patient to achieve improved prediction performance, also known as multi-view learning.
Multi-view/ multi-modal learning [84, 85] are machine learning techniques for building
models that can integrate multiple types of input information (called ‘views’ or ‘modalities’
in the literature). For example, in the biomedical field, a patient’s electronic health records
(EHRs), personal health records (PHRs), genomic and proteomic variations, and medical
images can be considered various views. Ideally, these multi-view data should be jointly
evaluated to realize a more personalized diagnosis and treatment.
The most naive approach is to treat the multi-view learning problem as a single-view
problem, where all views are concatenated into a single view and then solved with the
established single-view models. However, as the feature concatenation ignores the inter-
actions between views and the number of features increases as the number of modalities
increases, this naive multi-view method’s performance can be sub-optimal with issues such
as over-fitting.
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To exploit the multi-view data, we have to consider the interactions among modalities.
There are two principles in multi-view learning [84]: 1) the consensus principle, which
assumes that the disagreement between views upper bounds the classification errors. Thus,
we should aim to maximize the agreement between views. 2) the complementary prin-
ciple, which assumes that each view contains information other views do not have, and
we should extract the difference from each view while preserving the shared information.
Researchers have developed two approaches, model-agnostic and model-based, based on
these two principles to combine data from multiple modalities.
Model-agnostic approaches are simple in design and usually utilize the complementary
principle. Based on when data from different modalities are integrated, we have early
integration (where we concatenate the raw/pre-processed features), late integration (where
we combine the output from each learning algorithm), and hybrid integration (where we
use early and late integration together).
Model-based approaches design models for integrating different modalities: 1) kernel-
based algorithms, mainly multiple kernel learning (MKL) [63], first compute kernel matri-
ces for each modality, then combines kernels in a linear or non-linear fashion for succeeding
kernel-based classification or regression algorithms. As kernels evaluate the similarities be-
tween data points, using modality-specific kernels helps capture heterogeneous information
from each modal and improves the performance. Kernel methods are especially helpful for
small sample sizes but suffer from high computational complexity when sample sizes are
large. 2) graphical models such as Bayesian networks and Markov random fields are a class
of algorithms that treat each feature as a random variable and exploit the probability rela-
tionships among them [86]. This approach’s benefit is that we can incorporate more priors
into our modeling and easily interpret the models. However, graphical models are also
computationally expensive. 3) deep learning-based multi-modal learning algorithms [87]
gain increasing popularity in the literature for the past few years. We design a modality-
specific neural network for feature extraction for each modality, and the extracted features
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can be fused for downstream analysis. This approach’s benefit is that deep neural networks
excel in extracting non-linear features and can easily incorporate additional regularization.
Popular architectures for deep learning-based multi-modal integration include joint repre-
sentation, coordinated representation, and cross-modality autoencoders [88]. The whole
architecture can be trained end-to-end with gradient-based optimization algorithms, mak-
ing the approach scalable to large sample scenarios.
2.2.2 Multi-modal Learning in Biomedical Science
With the development of data collection technologies in the biomedical domain, researchers
now have access to various multi-modal data such as high-throughput multi-omics data
(e.g., gene expression, DNA methylation, and single nucleotide polymorphisms (SNPs)),
medical imaging data (e.g., pathology and radiology), and clinical records (e.g., demo-
graphics, insurance claims, and past medication history).
Based on characteristics of the modality available, researches have designed various
task-specific multi-modal learning algorithms in recent biomedical research [89, 90]. In
the sub-filed of -omics data analysis, various multi-modal learning methods have been pro-
posed for multi-omics integration. For example, Xu et al. [91] studied how to integrate
-omics data using graph-based similarity between molecular information such as gene ex-
pression and DNA methylation and showed superior performance in cancer types classifi-
cation and survival prediction. Vasaikar et al. [92] created a database of over one billion
data points by combining multi-omics data and clinical data from the TCGA dataset for
32 cancer types with the proteomics data. In addition, they presented a module for ana-
lyzing and visualizing associations between clinical and molecular attributes. Way et al.
[93] integrated RNA-seq, copy number variations, and mutations for identification of ab-
normal molecular states in tumors. Ma et al. [81] studied how to integrate multi-omics data
using neural network-based approaches by combining multiple autoencoders and how do-
main knowledge can be incorporated to improve the learned representations. The improved
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Figure 2.2: Two application scenarios for consensus and complementary principles. A.
For dependent modalities such as multi-omics, we can apply the consensus principle for
integration. B. For independent modalities such as gene+environmental data, we can apply
the complementary principle for integration.
representations outperform other integration methods in predicting disease progression on
TCGA datasets. A similar autoencoder-based approach has been proposed by Chaudhary
et al. [94], where they used k-means clustering to identify survival-risk subgroups and
showed that integration of mRNA, miRNA, and DNA methylation improved the survival
prediction for cancer patients. Huang et al. [82] integrated intermediate representations
from multi-layer perceptrons and showed improved performance on cancer survival pre-
diction on select TCGA datasets.
Based on multi-view learning’s complementary and consensus principles, we have iden-
tified two application scenarios for biomedical multi-modal data integration: dependent
and independent modalities. For dependent modalities that are closely related to each other
(e.g., multi-omics) through association/causal relationships, we propose to capture the in-
teractions among modalities through the consensus principle. For independent modalities
that are less connected to each other (e.g., various environmental and lifestyle factors), we
propose to combine the multi-modalities through the complementary principle (Figure 2.2).
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Figure 2.3: Integrating independent multi-modal biomedical data with complementary
principle. We can apply modality-specific deep networks for each data modality indepen-
dently and then combine the hidden features learned for each modality by concatenation.
To integrate independent multi-modal biomedical data with complementary principle, we
propose a straightforward framework by first applying modality-independent feature repre-
sentations and then combining the hidden features learned for each modality by concatena-
tion (Figure 2.3). We have applied the proposed intermediate feature-level concatenation-
based integration methods to the prediction of Alzheimer’s disease in the following section.
2.3 Multi-modal data integration for early detection of Alzheimer’s disease
2.3.1 Background
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and forms the
sixth leading cause of death in the United States. The worldwide disease burden of AD is
predicted to reach $2 trillion by 2030. Thus, the early detection of AD is essential to re-
duce the cost while improving healthcare quality. Despite extensive research and advances
in clinical practice, less than 50% of the people with AD are being diagnosed accurately
for their pathology and disease progression based on their clinical symptoms. The most
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conclusive evidence for Alzheimer’s diagnosis is the presence of amyloid plaques and neu-
rofibrillary tangles in histopathology. However, the early onset of AD is not correlated with
plaque presence, but with synaptic and neuronal loss [95].
Research on data from Alzheimer’s disease initiative and data mining strategies for AD
[96, 97, 98] are being undertaken to improve our understanding of the underlying disease
processes. AD biomarkers including clinical symptoms [99] (e.g., dementia and memory
loss) and neurological test scores (e.g., MMSE scores) are being augmented with imag-
ing, genetic, and protein-related biomarkers [100, 101, 102, 103]. Most of these studies
identify biomarkers using a single-modality data, which restricts holistic assessment of AD
disease progression. Thus, there have been AD multi-modal analyses that combine various
imaging modalities [104, 105, 106, 107, 108, 109] such as structural MRI (T1 weighted,
T2 weighted), fMRI and PET [110, 111], and imaging genetics [112]. In addition, genetics
have been used with clinical data to augment data labels and phenotypes. Besides shallow
learners, DL models such as auto-encoders [113] and deep-belief networks [114] have been
used for PET and MRI image data fusion with improved prediction.
In this case study, we further the multi-modal AD data fusion to advance AD stage
prediction by using DL to combine imaging, EHR, and SNP data to classify patients into
control, MCI, and AD groups. We use stacked denoising autoencoders for EHR and SNP
data feature extraction and novel 3D CNNs for MRI imaging data. After the networks are
separately trained for each data modality, we combine them using different classification
layers, including decision trees, random forests, support vector machines (SVM), and k-
nearest neighbors (kNN). We demonstrate the performance of our integration models using
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [115] dataset that contains SNP
(808 patients), MR imaging (503 patients), and clinical and neurological test data (2,004
patients). The proposed intermediate-feature-level integration using novel DL architectures




The data we use in this case study are obtained from the ADNI database (adni.loni.usc.edu)
[115]. The primary goal of ADNI is to measure the progression of mild cognitive im-
pairment (MCI) and early AD by combining serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and neuropsy-
chological assessments. The ADNI data repository contains imaging, clinical and genetic
data for over 2,220 patients spanning over four studies (ADNI1, ADNI2, ADNI GO, and
ADNI3). Our study focuses on ADNI1, 2, and GO because ADNI 3 is an ongoing study
due to end in 2022. The data is currently being released in phases with limited availability
for imaging (unprocessed) and no genetic data yet. The imaging data (ADNI1, 2, and GO)
consists of MRI and PET images, of which we use cross-sectional MRI data corresponding
to the baseline screenings from ADNI1 (503 patients). The data publisher has standardized
the images to eliminate the non-linearities caused by the scanners from different vendors.
For clinical or EHR data, we use 2,004 patients (ADNI1, ADNI2, and ADNI GO) data
from the clinical tests (e.g., memory tests, balance tests, and cognitive tests), medication
data (e.g., usage of levodopa), imaging score summaries (e.g., levels of FDG from PET,
brain volumes from MRI), patient demographics (e.g., age and gender), and biochemical
tests. The genetic data consists of the whole genome sequencing (WGS) data from 808
ADNI participants (at the time of sequencing, 128 with AD, 415 with MCI, and 267 con-
trols), sequenced by Illumina’s non-CLIA laboratory at roughly 30-40x coverage in 2012
and 2013. The resulting variant call files (VCFs) have been generated by ADNI using
Broad best practices (BWA and GATK-haplotype caller) in 2014. In this study, we use a
total of 2,004 patients for whom clinical data were available, 503 patients with imaging
data (9,108 voxels per patient distributed over 18 slices, with each slice having 22×23 vox-
els), and 808 patients with genetic data (Table 2.1). For participants with multiple visits,
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Table 2.1: A summary of the ADNI data
CN MIC AD Example Data Types/Features
Clinical Data 598 699 707
Demographics, neurological exams,
cognitive assessments,
bio-markers (e.g. alanine, choline),
medication (e.g. levodopa),
imaging summary scores (e.g. brain are volumes)
Imaging Data 132 104 266 Cross-sectional MRI data
Genetic Data 245 338 226 SNPs obtained fromwhole genome sequencing (WGS) data
Figure 2.4: Venn diagram of the ADNI data. 220 patients had all the three data modalities,
588 patients had SNP and EHR, 283 patients had imaging and EHR, the remaining patients
had only EHR data.
we use the diagnosis from the patient’s last visit. As shown in Figure 2.4., 220 patients
have all three data modalities, 588 patients have SNP and EHR, 283 patients have imaging
and EHR, the remaining patients have only EHR data
Multi-modal data integration
We use the multi-modal data with MR imaging (503 patients), SNPs (808 patients), and
the EHR (2004 patients) to predict AD stages. We first demonstrate the superiority of
deep models over shallow models such as kNN, one-vs-one coding SVM, random forests,
and decision trees for each single data modality. The SNP and EHR features for shallow
models and DL are the same. For imaging, when using DL, we apply multi-slice 3D voxels
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Figure 2.5: Deep Model for Data Integration Compared with Shallow Models of Data Inte-
gration. a) Feature level integration on shallow models, where the features are concatenated
before passing into shallow models. b) Deep intermediate feature level integration where
the original features are transformed separatelyusing deep models prior to integration and
prediction. c) Decision level integration where voting is performed using decisions of in-
dividual classifiers. In this study, we comparee the performance of deep intermediate level
integration against shallow feature and decision levels integrations for the prediction of
Alzheimer’s stages.
directly, while for shallow learners, we extract expert crafted features derived from the 3D
voxels.
Regarding AD staging, only EHR has three-stage classes CN, AD, and MCI. SNP ex-
pression does not vary between MCI and AD [117], and only has CN vs. AD/MCI predic-
tion. On images, patients with early MCI were structurally similar to CN, and those from
patients with late MCI were structurally similar to AD [118]. Thus, only controls (CN)
and Alzheimer’s disease (AD) are used for staging assessment for imaging data. Thus,
combining all three modalities can help us significantly improve AD staging prediction
accuracy.
We have developed three data fusion strategies: 1) Feature-level combinations using
shallow models, 2) Intermediate-feature-level combinations using deep models, and 3)
Decision-level combinations using shallow models (Figure 2.5).
Feature-level combinations are performed through a direct concatenation of the data
modalities using shallow learners (Figure 2.5). The intermediate-feature-level combination
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is performed by extracting intermediate features using DL, which is then concatenated and
passed through a classification layer. Decision-level combinations are performed through
voting on the single-modalities. We test shallow models such as kNN, one-vs-one coding
SVM, random forests, and decision trees for decision-level combinations and present the
best performing model. For the intermediate-feature-level models (Figure 2.6), we evaluate
four combinations: 1) EHR + imaging + SNP, 2) EHR + imaging, 3) EHR+ SNP, and
4) imaging + SNP. For all combinations except imaging + SNP, we perform three-stage
classification (CN, AD, and MCI). For imaging + SNP, we perform classification into AD
vs. CN.
All cases mentioned above are evaluated using internal cross-validation and an external
test set. We first remove 10% of the data as an external test set. On the remaining 90%, we
perform 10-fold cross-validation with 81% of the total data being used for training and 9%
for internal cross-validation. The internal cross-validation data set is used to optimize the
model.
2.3.3 Results
We report the ADNI results for both the internal cross-validation partition and the external
test dataset. For each of the DL models and the shallow models as baselines, we use mean
values of accuracy, precision, recall, and meanF1 scores as metrics to show the superiority
of deep models for single-modalities and the improvements gained from data integration.
3D Convolutional Neural Network (DL) is Superior to Shallow Models on Imaging MRI
Data
One patient’s imaging data consists of 9,108 3D voxels of dimension 22×23×18, corre-
sponding to each of the five selected brain areas. The number of nodes in DL models for
the first-level fully connected layers is 5 × 20 = 100, and the number of nodes for the
second level fully connected layer is 20. The results (Figure 2.7a.) indicate that the CNN
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Figure 2.6: Intermediate-Feature-Level Combination Deep Models for Multimodality Data
Integration for Clinical Decision Support. Data from diverse sources, imaging, EHR
and SNP are combined using novel deep architectures. 3D convolutional neural net-
work architectures used on 3D MR image regions to obtain intermediate imaging fea-
tures. Deep stacked denoising autoencoders are used to obtain intermediate EHR features.
Deep stacked denoising autoencoders are used obtain intermediate SNP features. The 3
types of intermediate features are passed into a classification layer for classification into
Alzheimer’s stages (CN, MCI and AD).
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based imaging models outperform shallow models and give the best precision and meanF1
scores.
Deep Autoencoder Model is Comparable to Shallow Models on EHR Data
EHR data consists of 2,004 patients with 1,680 normalized features per patient, which we
use to classify the patients into AD, MCI, and controls (three class). We use a three-layer
auto-encoder with 200, 100, and 50 nodes each. The deep networks are trained using Adam
with a max epoch count (repetition of DL network training on the entire dataset to allow
adequate training) of 25. After hyperparameter optimization, the regularization coefficients
for initial training is fixed at 0.03 and those for fine-tuning at 0.03. The dropout probability
is set to 0.6 for all the layers. The results (Figure 2.7b.) indicate that the autoencoders
outperform shallow models such as kNN and SVM, and they are comparable to decision
trees and random forests.
Deep Autoencoder Model is Superior to Shallow Models for SNP Data
Processed SNP data consists of 808 patients with 500 features (each with levels 1,2,3),
which we use to classify them into AD/MCI vs. controls (two-class). Autoencoder network
consists of three hidden layers with 200, 100, and 50 nodes each. Using Adam optimization
and a max epoch count of 30, the best performing models have regularization coefficients
for initial training as 0.03 and those for fine-tuning at 0.06. The corruption (dropouts) is 0.6
for each layer. The results (Figure 2.7c.) indicate that the autoencoder models outperform
all the baseline models.
Results for Multi-Modality Classification
The intermediate features generated from the single-modality deep-models are concate-
nated and passed to an additional classification layer for integration.
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Figure 2.7: Internal Cross Validation Results for Individual Data Modality to Predict
Alzheimer’s Stage a) Imaging Results: Deep learning prediction performs better than shal-
low learning predictions b) EHR Results: Deep learning outperforms shallow models kNN
and SVM and is comparable to decision trees and random forests c) SNP Results: Deep
learning outperforms shallow models. The kNN, SVM , RF and decision trees are shallow
models. ((kNN: k-Nearest Neighbors, SVM: Support Vector Machines, and RF: Random
Forests).
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Figure 2.8: Internal Cross Validation Results for Integration of Data Modalities to Predict
Alzheimer’s Stage. a) Imaging + EHR + SNP: Deep learning prediction performs better
than shallow learning predictions. b) EHR + SNP: Deep learning prediction performs better
than shallow learning predictions. c) Imaging + HER: Deep learning prediction performs
better than shallow learning predictions. d) Imaging + SNP: Shallow learning gave a bet-
ter prediction than deep learning due to small sample sizes. (kNN: k-Nearest Neighbors,
SVM: Support Vector Machines, RF: Random Forests, SM: Shallow Models, and DL: Deep
Learning).
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Combination of all three modalities: (Imaging + EHR + SNP): Deep Model Outperforms
Shallow Models
When a particular modality is not available, we mask it as zeros when using DL. The
intermediate features from the three modalities are passed to the classification layer. We
test kNN, decision trees, random forests, and support vector machines as alternatives for
the classification layer. Internal cross-validation (CV) accuracy (Figure 2.8a) using deep
models followed by random forests as the classification layer are the best. Deep models for
the combination of the three modalities outperform single-modalities DL. In addition, the
deep model outperforms shallow models such as feature-level and decision-level for both
CV and external test sets during combination.
Combination of SNP and EHR modalities: Deep Model Outperforms Shallow Models
Internal CV accuracy of 0.78 ± 0 using deep models followed by random forests as the
classification layer (Figure 2.8b.) is the best. The deep models for EHR + SNP combina-
tions outperform single-modalities DL. The deep model outperforms shallow models such
as feature-level combination models for both CV and external test sets during combination.
Combination of Imaging and EHR modalities: Deep Model Outperforms Shallow Models
Internal CV accuracy of 0.79± 0 using deep models followed by random forests and SVM
as the classification layers (Figure 2.8c.) are the best. The deep models for EHR + imaging
combinations outperform single-modalities DL. In addition, the DL model outperforms
shallow models such as feature-level and decision-level combination models for both CV
and external test sets during combination. Random forests as the classification layer give
the best performance on the external set.
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Combination of Imaging and SNP modalities: Shallow Model Outperforms Deep Models
We perform two-class classification using a combination of SNP and imaging intermedi-
ate features (CN vs. AD/MCI). Internal CV accuracy of 0.75 ± 0.11, using feature-level
combination models (Figure 2.8d) is the best. However, the results on the external data
are poor. The DL model’s performance drop can be attributed to the small overlap of 220
samples between the two modalities. More details of the methods and results can be found
in [116].
2.3.4 Concolusion and discussion
For single-modality classification, the DL-based models outperform the shallow models.
The hand-crafted features could be the bottleneck for shallow models, which require human
expertise and limit the model capability. On the contrary, deep networks can automatically
learn optimal feature representations from the training data based on specific objectives.
For example, the deep autoencoders learn the feature representation in an unsupervised
fashion by reconstructing the input.
Integration of multiple modalities improves the prediction accuracy (three of four sce-
narios). The deep models for integration also show improved performance over traditional
feature-level and decision-level integrations except for the integration of Imaging and SNP
data, which are limited by the small number of training data.
One bottleneck for our proposed DL-based data integration performance is the small
sample size of the ADNI dataset. To mitigate the sample size challenge, we can utilize
strategies such as transfer learning and domain adaptation [118]. For each data modal-
ity, we can adopt neural networks pre-trained on other similar datasets (e.g., CNN-based
MRI/CT brain imaging classification model trained for other conditions). By composing
our model with these pre-trained networks and their parameters, we can perform domain
adaptation or fine-tune the network parameters using our labeled ADNI data. On the other
hand, we can also perform an unsupervised feature representation learning for each data
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modality using publicly available data (e.g., The Cancer Genome Atlas (TCGA) dataset for
SNPs). On the other hand, our feature extraction step is performed independently for each
modality, which is not trained end-to-end with the integration and classification step. One




INTEGRATING MULTI-OMICS DATA WITH CONSENSUS LEARNING
In the previous chapter, we have applied intermediate feature-level concatenation to inte-
grate multi-modal data from independent modalities. In this chapter, we will discuss the
integration of multi-modal data from dependent modalities. We will focus on integrating
multi-omics data (e.g., gene expression and DNA methylation), which are assumed to be
connected by associations or causal relationships. We will first present our work on the
evaluation of bioinformatics pipelines for gene expression estimation. We will then present
two frameworks on the integration of multi-omics data using the consensus principles.
3.1 Impact of RNA-seq Data Analysis Algorithms on Gene Expression Estimation
and Downstream Prediction
To use next-generation sequencing technology such as RNA-seq for medical and health
applications, choosing proper analysis methods for biomarker identification remains a crit-
ical challenge for most users. The US Food and Drug Administration (FDA) has led the
Sequencing Quality Control (SEQC) project to conduct a comprehensive investigation of
278 representative RNA-seq data analysis pipelines consisting of 13 sequence mapping,
three quantification, and seven normalization methods. In this study, we focused on the
impact of the joint effects of RNA-seq pipelines on gene expression estimation as well
as the downstream prediction of disease outcomes. First, we developed and applied three
metrics (i.e., accuracy, precision, and reliability) to evaluate each pipeline’s performance on
gene expression estimation quantitatively. We then investigated the correlation between the
proposed metrics and the downstream prediction performance using two real-world cancer
datasets (i.e., SEQC neuroblastoma dataset and the NIH/NCI TCGA lung adenocarcinoma
dataset). We found that RNA-seq pipeline components jointly and significantly impacted
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the accuracy of gene expression estimation, and its impact was extended to the downstream
prediction of these cancer outcomes. Specifically, RNA-seq pipelines that produced more
accurate, precise, and reliable gene expression estimation tended to perform better in the
prediction of disease outcome. In the end, we provided scenarios as guidelines for users
to use these three metrics to select sensible RNA-seq pipelines for the improved accuracy,
precision, and reliability of gene expression estimation, which lead to the improved down-
stream gene expression-based prediction of disease outcome [119].
3.1.1 Introduction to RNA-seq pipelines evaluation
The first phase of the FDA-led microarray quality control project (MAQC-I) investigated
the reliability of microarray platforms for gene expression estimation [52]. The second
phase of the project, MAQC-II, studied 30,000+ microarray data analysis pipelines to as-
sess the reproducibility of microarray-based predictive models [120]. Given the rise of the
significance of next-generation sequencing in gene expression analysis, the FDA initiated
the sequencing quality control project (SEQC) as a continuing MAQC effort to conduct
an in-depth assessment of RNA-seq by combining the objectives of both MAQC-1 and
MAQC-II [121, 122, 123, 124]. Specifically, the goal of SEQC was to conduct a com-
prehensive evaluation of both RNA-seq technology and RNA-seq data analysis pipelines,
which was similar to the objectives of MAQC-I and MAQC-II for microarrays. While Su
et al. summarized the RNA-seq technology investigation [53], this complementary study
focuses on the RNA-seq data analysis pipelines targeting medical and health applications.
Specifically, this study examines the effect of RNA-seq pipelines on gene expression with
three critical metrics (i.e., accuracy, precision, and reliability), and further on downstream
gene expression-based prediction of disease outcomes. Although other analyses of RNA-
seq are possible (e.g., differential expression analysis [125, 126, 127], alternative splicing
[128, 129, 130], and RNA fusion [131, 132]), we focus on gene expression because it is the
most widely used genetic variations in biomedical and health applications.
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For medical and health applications, choosing a proper RNA-seq gene expression anal-
ysis pipeline remains a critical challenge due to its relative immaturity (i.e., fewer standards
reported compared with microarrays), complexity, and diverse applicability [133, 134]. We
performed a literature survey on RNA-seq pipelines consisting of sequence mapping [135,
136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146], expression quantification [147, 148,
149, 150], and expression normalization [124, 151, 152, 153]. For evaluation of RNA-seq
pipelines, the majority strategy is to use some sorts of benchmark datasets, or reference
standards to enable quality control [154] (e.g., natural well-characterized genetic materials
or synthetic spike-in controls). For benchmark dataset-based evaluation, multiple compara-
tive investigations exist for focusing on individual components of RNA-seq pipelines, such
as mapping alone [142, 155, 156, 157, 158, 159, 160], quantification only [150, 130, 161],
or normalization [151, 162, 163]. Correspondingly, the joint impact of each of these three
components is less understood. For examples, a previous analysis of 50 RNA-seq pipelines
examined combinations of ten mapping and five quantification algorithms, but it did not
study the effect of different normalization methods’ impact and the interaction effect among
pipeline components [164]; another study investigated three mapping, two quantification,
and five differentially expressed gene (DEG) detection methods, but it did not report the
interaction effect among components either [165]; a third study by Sahraeian et al. exam-
ined 120 combinations of 39 tools 14 for RNA variant calling, RNA editing, RNA fusion,
gene expression, and differential expression, but it did not provide an assessment on their
impact on gene-expression-based downstream prediction. Most FDA approvals on medical
genomics would be relevant to gene expression applications. To the best of our knowledge,
no studies have comprehensively examined the joint effect of RNA-seq pipeline compo-
nents on gene expression and its downstream prediction of disease outcomes. Thus, this
study dedicates to this goal.
The FDA coordinated multiple sites of SEQC to generate a multi-replicate benchmark
dataset (referred to as SEQC-benchmark) [53] and a clinical dataset consisting of neurob-
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lastoma patient samples (referred to as SEQC-neuroblastoma) [166]. In addition, we have
another real-world clinical dataset on lung adenocarcinoma (referred to as TCGA-lung-
adenocarcinoma) from The Cancer Genome Atlas (TCGA). These datasets were used to
investigate the joint impact of pipeline components on downstream gene expression-based
prediction in a two-phase study:
(1) Phase-1: we developed three metrics—accuracy, precision, and reliability—for as-
sessing the performance of a representative set of 278 RNA-seq pipelines (Figure 3.1, blue
box) using the SEQC-benchmark dataset (i.e., A, B, C and D where C is 75/25 of A/B
while D is 25/75 of A/B). (2) Phase-2: we validated the benchmark metrics by quantifying
gene expression in the SEQC-neuroblastoma dataset and the TCGA-lung-adenocarcinoma
dataset and demonstrated that the benchmark metrics are informative for inferring down-
stream prediction of disease outcome (Figure 3.1, pink box).
Our comprehensive investigation revealed that RNA-seq pipeline components—mapping,
quantification, and normalization—jointly impacted the accuracy, precision, and reliability
of gene expression, and affected the downstream performance of predicting neuroblastoma
and lung adenocarcinoma outcome. RNA-seq pipelines that performed well in gene ex-
pression estimation also performed well in downstream prediction of disease outcome.
3.1.2 Results
Phase-1: Assessing the joint impact of pipeline components on gene expression estimation
with the benchmark metrics
We systematically investigated 278 RNA-seq pipelines that included combinations of map-
ping, quantification, and normalization components. Sequence mapping algorithms were
further categorized based on mapping strategy (i.e., un-spliced and spliced) and mapping
reporting (i.e., single-hit and multi-hit) (refer to [119] for more details). To gain insight
into these pipelines, we used the SEQC-benchmark dataset and a quantitative PCR (qPCR)
benchmark dataset. Because the qPCR results vary among platforms [53], we filtered them
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Figure 3.1: The SEQC consortium developed and validated a guideline for selecting RNA-
seq pipelines for gene expression-based predictive modeling using the SEQC-benchmark,
SEQC-neuroblastoma, and TCGA-lung-adenocarcinoma datasets. Phase-1 of the inves-
tigation developed the metrics that captured the accuracy, precision, and reliability of
RNA-seq pipelines (the blue box). Using the SEQC-neuroblastoma and TCGA-lung-
adenocarcinoma datasets, Phase-2 of the investigation determined that RNA-seq pipeline
metrics can be used to select pipelines that result in better performance in terms of predict-
ing cancer outcome (the pink box).
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Figure 3.2: The 278 RNA-seq pipelines applied to the SEQC-benchmark dataset differ in
terms of gene expression accuracy, precision, and reliability. In each heatmap, the rows are
different settings for 13 aligners and the columns are combinations of three quantification
and seven normalization methods. (a) Accuracy is defined as the deviation of pipeline-
derived log ratios of gene expression from the corresponding qPCR-based log ratios. Me-
dian accuracy of all genes (i.e., 10,222 genes) is encoded as color, with red representing
the highest accuracy, or the lowest deviation from qPCR. (b) Precision is defined as the
coefficient of variation (CoV) of gene expression over replicate libraries. Median precision
of all genes is encoded as color, with red indicating the highest precision, or the lowest
CoV. (c) Reliability is defined as the intraclass (or intra-sample in our context) correlation
that quantifies how similar replicate libraries of a sample are to one another using anal-
ysis of variance techniques. Median reliability of all genes is encoded as color, with red
representing the highest reliability, or the highest intraclass correlation. Refer to [119] for
mathematical definitions of accuracy, precision, and reliability in the context of RNA-seq
pipelines.
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Figure 3.3: Analysis of variance decomposes the overall variance in (a) median accuracy
of all genes, (b) median precision of all genes, and (c) median reliability of all genes into
various factors considered, including five RNA-seq pipeline components (i.e., mapping
algorithm, mapping strategy, mapping reporting, quantification, and normalization) and
nine associated two-way interactions. The statistical significance of each component’s or
interaction’s contribution is denoted by red asterisks, with ‘***’ indicating p-values are
smaller than 0.001, ‘**’ indicating p-values are smaller than 0.01, and ‘*’ indicating p-
values are smaller than 0.05.
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to keep the genes that fit the titration ratio of A D samples. After filtering with the titration
ratio, we only used 10,222 genes (out of a total of 20,801 genes assayed with qPCR) as a
benchmark reference. We have applied three metrics (i.e., accuracy, precision, and reliabil-
ity) to evaluate each pipeline. These metrics are detailed in the published paper [119]. The
joint effect of mapping, quantification, and normalization with respect to these three met-
rics was assessed comprehensively for all genes (the entire set of 10,222 genes, referred
as AllGenes hereafter) and for the low-expression genes (2,044, the subset of AllGenes,
referred as LowExpressGenes hereafter).
We defined the accuracy metric as the deviation of RNA-seq pipeline-derived log ra-
tios of gene expression from the corresponding qPCR-based log ratios and visualized the
median accuracy of AllGenes and LowExpressGenes using heatmaps (Figure 3.2a). We
observed the following results:
(1) Using AllGenes, the log-ratio deviation between RNA-seq and qPCR ranged from
0.27 to 0.63 (Figure 3.2a). A smaller deviation represents higher accuracy. Median normal-
ization exhibited the lowest deviation, or the highest accuracy, compared with all other nor-
malization methods. In addition, for all mapping-quantification combinations, the [Bowtie2
multi-hit + count-based] pipelines showed the largest deviation. Moreover, pipelines with
multi-hit mapping and count-based quantification generally showed a larger deviation than
other pipelines. Among all pipeline factors, normalization was the largest statistically sig-
nificant (p < 0.05) source of variation (Figure 3.3a). (2) The log-ratio deviation using
LowExpressGenes was larger than that using AllGenes, and it ranged from 0.45 to 0.69.
The trends of pipeline performance were similar to those using AllGenes, and normaliza-
tion was also the largest statistically significant (p¡0.05) source of variation. (3) In sum-
mary, median normalization with most mapping and quantification algorithms, except for
the [Bowtie2 multi-hit + count-based] pipelines, was the best choice for quantifying genes
with high accuracy, or low deviation from qPCR.
We defined the precision metric as the coefficient of variation (CoV) of gene expres-
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sion across replicate libraries, and visualized the median precision of AllGenes and Low-
ExpressGenes using heatmaps (Figure 3.2b). We observed the following results:
(1) Using AllGenes, the CoV ranged from 6.30% to 7.96% (Figure 3.2b). Smaller
CoV represents higher precision. Pipelines with any of Novoalign, GSNAP un-spliced, or
WHAM mapping, and RSEM quantification resulted in higher CoV, or lower precision,
despite the choice of normalization methods. In addition, the [Bowtie2 multi-hit + count-
based + med.] pipeline led to the largest CoV. Moreover, for each mapping-normalization
combination, pipelines with either count-based or Cufflinks quantification reported higher
precision than those with RSEM quantification, except the [Bowtie2 multi-hit + count-
based + med.] pipeline mentioned previously. Quantification, mapping algorithm, and
their interaction were the largest statistically significant (p¡0.05) sources of variation (Fig-
ure 3.3b). (2) The CoV using LowExpressGenes was larger than that using AllGenes, and
it ranged from 11.0% to 15.6%. The trends of pipeline performance were similar to those
using AllGenes, except that the [Bowtie2 multi-hit + count-based] pipelines exhibited the
highest precision among others. Again, quantification, mapping algorithm, and their inter-
action were the largest statistically significant (p¡0.05) source of variation. (3) In summary,
pipelines with any of Bowtie2 multi-hit, GSNAP un-spliced, or Subread mapping and either
count-based or Cufflinks quantification, except for the [Bowtie2 multi-hit + count-based +
med.] pipeline, were the best choice for quantifying genes with high precision, or low CoV.
We defined the reliability metric as the intra-class (i.e., intra-sample in the context of the
SEQC-benchmark dataset) correlation (ICC) of gene expression, and visualized the median
reliability of AllGenes and lowExpressGenes using heatmaps (Figure 3.2c). We observed
the following results:
(1) Using AllGenes, the ICC ranged from 0.972 to 0.991 (Figure 3.2c). Larger ICC
represents higher reliability. Median normalization exhibited the highest ICC, or the high-
est reliability, compared with all other normalization methods. In addition, pipelines with
Novoalign mapping and RSEM quantification resulted in lower ICC for all but Median
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normalization. Moreover, the [Bowtie2 multi-hit + count-based] pipelines showed the low-
est ICC. Furthermore, for each mapping-normalization combination, pipelines with either
count-based or Cufflinks quantification always reported higher ICC than those with RSEM
quantification, except the [Bowtie2 multi-hit + count-based] pipelines mentioned previ-
ously. Normalization was the largest statistically significant (p < 0.05) source of variation
(Figure 3.3c), followed by two-way [mapping algorithm*quantification] interaction. (2)
The ICC using LowExpressGenes was smaller than that using AllGenes, and it ranged
from 0.938 to 0.975. The trends of pipeline performance were similar to those using All-
Genes, except that the [Novoalign + RSEM] pipelines exhibited the lowest ICC, followed
by the [Bowtie2 multi-hit + count-based] pipelines. Normalization, two-way [mapping al-
gorithm*quantification] interaction, quantification, and mapping algorithm were the largest
statistically significant (p < 0.05) sources of variation. (3) In summary, median normal-
ization along with most mapping and quantification algorithms, except for the [Bowtie2
multi-hit + count-based] and [Novoalign + RSEM] pipelines, was the best choice for quan-
tifying genes with high reliability, or high ICC.
We also examined whether the performance of metrics depended on the characteristics
of sequence mapping results. We used M-estimation with Huber weighting to fit robust
linear models that capture the relationship between the benchmark metrics and alignment
profiles. The accuracy metric correlated with the number of mismatches per mapped read,
and the precision and reliability metrics correlated with the number of mapped fragments.
Fewer mismatches per read and more mapped fragments tended to lead to more accurate,
precise, and reliable gene expression.
In summary, the Phase-1 investigation using the SEQC-benchmark dataset demon-
strated that gene expression estimation is significantly impacted by the joint effect of mul-
tiple RNA-seq pipeline components (Figures 3.2 and 3.3).
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Phase-2: The impact of RNA-seq pipeline on the disease outcome prediction performance
We used the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets to assess the
impact of upstream RNA-seq pipeline components on the downstream prediction of disease
outcome using gene expression (Figure 3.1). The SEQC-neuroblastoma dataset, provided
by the SEQC consortium, contains RNA-seq data of 176 primary neuroblastomas obtained
from high-risk patients with well-annotated clinical data [166], in which survival informa-
tion, including event-free survival (EFS) and overall survival (OS), was used for defining
group labels. The TCGA-lung-adenocarcinoma dataset contains RNA-seq data of patients
with known survival time used for defining group labels.
We used the same set of 278 RNA-seq pipelines to process the SEQC-neuroblastoma
dataset (we used only 156 out of the 278 pipelines for the TCGA-lung-adenocarcinoma
dataset). For each set of estimated gene expression (278 for neuroblastoma and 156 for lung
adenocarcinoma), we performed nested cross-validation using three classifiers—adaptive
boosting, logistic regression, and support vector machines, which are proven to be robust
and mostly used in machine learning. For each clinical endpoint—neuroblastoma EFS,
neuroblastoma OS, and lung adenocarcinoma survival—we calculated the AUC (area under
the ROC curve) and MCC (Matthews correlation coefficient), and visualized these using
heatmaps. We observed the following results:
(1) For the neuroblastoma EFS endpoint, pipelines using count-based quantification
with TMM, RLE, upper quartile, or median normalization tended to achieve high AUC and
MCC; while those with FPM or FPKM normalization tended to perform poorly. In addition,
Novoalign with Cufflinks and Bowtie2 or BWA with RSEM led to poor AUC and MCC,
especially when combining with FPM or FPKM normalization. (2) For the neuroblastoma
OS endpoint, median normalization led to higher AUC and MCC than other normaliza-
tion methods for most mapping-quantification combinations. GSNAP un-spliced mapping
performed well with count-based or Cufflinks quantification but not RSEM quantification.
In addition, pipelines with RSEM quantification and any of upper quartile, RLE, or TMM
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normalization tended to result in poor AUC and MCC. (3) For the lung adenocarcinoma sur-
vival endpoint, pipelines with count-based quantification and TMM normalization tended
to achieve high AUC and MCC. TopHat alignment with either count-based or Cufflinks
quantification also performed well. In contrast, pipelines with any of Novoalign single-
hit, STAR, GSNAP un-spliced multi-hit, or Bowtie2 multi-hit and Cufflinks resulted in
lower AUC and MCC. (4) ANOVA for each neuroblastoma endpoint showed that normal-
ization was the largest statistically significant (p < 0.05) source of variation, followed by
mapping algorithm, two-way [mapping algorithm*quantification] interaction, and two-way
[quantification*normalization] interaction. For the lung adenocarcinoma endpoint, several
pipeline components and their interactions contributed more evenly to the overall variance
that may be due to only 156 pipelines were conducted. All ANOVA reported large residual
variance that should be explained by higher-order interactions.
These results suggested that the choice of upstream RNA-seq pipeline components sig-
nificantly impacted the performance of downstream prediction of disease outcome. We
summarized the predictive modeling performance for the 278 and 156 RNA-seq pipelines
applied to the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets, respec-
tively.
We ranked the 278 RNA-seq pipelines base on the average rank of a combination of the
three metrics. The top 10% pipelines were chosen as the good-performing pipelines, while
the bottom 10% pipelines were chosen as the poor-performing pipelines. We then com-
pared good-performing versus poor-performing pipelines in conducting gene-expression-
based prediction of disease outcome and the success rates of patient stratification for the
three endpoints. The comparison was assessed with the one-sided Wilcoxon rank-sum test
(Figure 3.4).
For the prediction of neuroblastoma OS endpoint, average prediction performance (i.e.,
AUC and MCC) of good-performing pipelines was statistically significantly (p¡0.05) larger
than that of poor-performing pipelines (Figure 3.4a and Figure 3.4b). For the prediction of
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Figure 3.4: RNA-seq pipelines selected based on benchmark metrics (i.e., accuracy, pre-
cision, and reliability) were informative for inferring the performance of gene-expression-
based prediction of disease outcome—(a) prediction performance measured by the area un-
der the receiver operating characteristic curve (AUROC, or AUC) for the overall survival
(OS) endpoint of the SEQC-neuroblastoma (NB) dataset; (b) prediction performance mea-
sured by the Matthews correlation coefficient (MCC) for the OS endpoint of the SEQC-NB
dataset; (c) prediction performance measured by the AUC for the event-free survival (EFS)
endpoint of the SEQC-NB dataset; (d) prediction performance measured by the MCC for
the EFS endpoint of the SEQC-NB dataset; (e) prediction performance measured by the
AUC for the survival endpoint of the TCGA-lung-adenocarcinoma (LUAD) dataset; and
(f) prediction performance measured by the MCC for the survival endpoint of the TCGA-
LUAD dataset. The red line in each panel shows the probability density of the prediction
performance of good-performing RNA-seq pipelines selected based on benchmark met-
rics; and the blue line demonstrates that of poor-performing pipelines selected based on the
same. Statistical significance (i.e., p-values) was determined using the one-sided Wilcoxon
rank-sum test. Panels (a), (b), and (d) show a statistically significant difference (p¡0.05)
between the two groups (i.e., the prediction performance of good-performing pipelines vs.
that of poor-performing pipelines). The good-performing (Top 10%) and poor-performing
pipelines (Bottom 10%) were determined based on the average rank of each RNA-seq
pipeline over all benchmark metrics of both all and low-expressing genes.
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neuroblastoma EFS endpoint, the average MCC of good-performing pipelines was statisti-
cally significantly (p¡0.05) larger than that of poor-performing pipelines (Figure 3.4c), and
the average AUC of good-performing pipelines was larger than that of poor-performing
pipelines with p slightly larger than 0.05 (Figure 3.4d). For the prediction of LUAD sur-
vival endpoint, average prediction performance (i.e., AUC and MCC) of good-performing
pipelines was larger than that of poor-performing pipelines (Figure 3.4e and Figure 3.4d)
but also with p slightly larger than 0.05.
In addition, good-performing pipelines (e.g., the [GSNAP un-spliced single-hit + Cuf-
flinks + median] pipeline) tended to result in higher success rates of patient stratification
than poor-performing pipelines (e.g., the [BWA + RSEM + RLE] pipeline). Figure 3.5
demonstrates Kaplan-Meier estimated survival functions for high-risk and low-risk patients
for all endpoints. Good-performing pipelines tended to achieve statistically significant sep-
aration (p¡0.05) of the two patient groups (Figure 3.5a-c), while poor-performing pipelines
were more likely to fail (Figure 3.5d-f). We have summarized the success rates of patient
stratification (i.e., p < 0.05 based on the two-tailed log-rank test) for the 278 and 156
RNA-seq pipelines applied to the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma
datasets, respectively.
3.1.3 Conclusion and Discussion
We performed a systematic investigation of the 278 representative RNA-seq pipelines in
two sequential phases. In Phase-1, we developed three metrics to characterize RNA-seq
pipelines using the SEQC-benchmark dataset: 1) accuracy measures gene expression es-
timation against the qPCR ground truth results, providing justification to support down-
stream biological interpretation; 2) precision assesses the fluctuation of such a measure-
ment across replicates, estimating the measurement behavior; 3) reliability: the consis-
tency of such a measurement among all the samples, offering the confidence of such a
measurement. All these metrics are of great value to support the downstream biological
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Figure 3.5: The RNA-seq pipeline selection guide was validated by assessing the ability of
pipelines to stratify patients based on Kaplan-Meier survival analysis. For each pipeline,
patients were grouped by predictive labels (i.e., high risk vs. low risk), and two Kaplan-
Meier curves were plotted. The two-tailed log-rank test was used to determine the statistical
significance of the separation between the two curves. For good-performing pipelines se-
lected based on benchmark metrics, the success rates of patient stratification (i.e., predictive
labels led to a statistically significant separation of Kaplan-Meier curves) were higher. For
example, the success rates of the [GSNAP (un-spliced, single-hit) + Cufflinks + Median]
pipeline were 93%, 70%, and 67% for the SEQC-NB OS, SEQC-NB-EFS, and TCGA-
LUAD-Survival endpoints, respectively. Panels (a) to (c) demonstrate the most statistically
significant separation of the two Kaplan-Meier curves for each endpoint. In contrast, poor-
performing pipelines led to lower success rates of patient stratification. For instance, the
success rates of the [BWA (un-spliced, single-hit) + RSEM + RLE] pipeline were 33%,
30%, and 33% for the SEQC-NB OS, SEQC-NB-EFS, and TCGA-LUAD-Survival end-
points, respectively. Panels (d) to (f) demonstrate the least statistically significant separa-
tion of the two Kaplan-Meier curves for each endpoint.
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interpretation of gene expression results. We observed that RNA-seq pipeline components
jointly affected gene expression estimation (Figures 3.2 and 3.3). This comprehensive in-
vestigation provides a framework to assist pipeline selection, which had not previously
been reported where individual RNA-seq pipeline components are usually focused (e.g.,
mapping [159]).
We have summarized and compared the results of our study to previous studies focus-
ing on individual pipeline components. For example, previous studies observed that RUM,
GSNAP spliced, STAR, and MapSplice mapping led to more accurate base-level alignment
and splice junction detection [142, 156]. In addition, BWA, Bowtie, and Bowtie2 mapping
were reported to be robust to sequencing errors and indels [155]. We similarly observed
considerable differences in alignment profiles among mapping algorithms, and such differ-
ences led to variations in the benchmark metrics. For example, Bowtie2 multi-hit mapping
aligned many more reads, a higher percentage of which were sub-optimal mapping variants
(i.e., secondary mappings, mismatches, insertions, deletions, and splicing) than WHAM
single-hit mapping. Consequently, pipelines with Bowtie2 multi-hit mapping resulted in
a larger deviation from the qPCR reference, or lower accuracy, than those with WHAM
single-hit mapping. However, such the observation applied to only count-based quantifica-
tion but not Cufflinks or RSEM (Figure 3.2a). In addition to the observations corresponding
to previous literature, we also observed a joint effect between mapping and quantification
components.
Variations in mapping performance propagated to the quantification stage. The quan-
tification strategy for multi-hit mappers may explain the variation in gene expression accu-
racy. For example, Cufflinks and RSEM use Poisson distribution-based models and assign
probabilities to each mapping, while HTSeq simply counts total mapped reads regardless
of quality. Thus, Cufflinks and RSEM can better handle multi-hit information, resulting in
a smaller deviation from the qPCR reference (Figure 3.2a). It is worthwhile to point out
that, although variation in performance was observed for different pipelines investigated,
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singling out one pipeline for general application is not justified. This is specifically true
by giving the fact that the joint effect of multiple components plays a role. Therefore, we
aim to demonstrate the importance of pipeline selection and their impact on downstream
analysis, such as classification.
In Phase-2, using the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets,
we showed that RNA-seq pipelines with better performance in gene expression estimation
(using average ranks of three metrics) resulting in a better downstream prediction of disease
outcome. Subsequently, we demonstrated the effect of pipeline selection on patient strat-
ification and provided a guideline for pipeline selection. Compared to previous RNA-seq
pipeline evaluation studies that were restricting on genetic variations (e.g., gene fusions)
[131], we have extended the scope to downstream applications such as survival predictions
using gene expression. The results revealed that RNA-seq pipelines jointly impact the gene
expression estimation, and the influence will carry on to downstream applications. Most
importantly, we found that RNA-seq pipelines that produced more accurate gene expression
resulted in better survival prediction performance.
Putting our results in the context of real-world application, we offer the following sce-
narios by taking advantage of our findings:
In scenario 1 where researchers need to select a pipeline to analyze an Illumina dataset
(or similar short-read sequence dataset), they may refer to our evaluation results to choose a
pipeline by following these steps (Figure 3.6): (1) Select a metric based on the requirements
of the clinical application (not necessarily predictive modeling). (2) Sort the pipelines
based on this metric and choose the top pipeline. For example, depending on the applica-
tion, different weights can be assigned to the three metrics instead of using the average rank.
Researchers who want to conduct initial filtering of genes to identify DEGs may want to
stress the importance of correct quantification of relative gene expression. Thus, they may
want to focus on the accuracy metric. Top and bottom pipelines in terms of accuracy are
listed in Figure 3.6a. Median normalization is the frequently occurring component in the
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(a) Good-performing RNA-seq pipelines for various applications.
(b) Use scenarios for SEQC benchmark datasets, RNA-seq pipelines, and benchmark metrics.
Figure 3.6: The resources provided by this study (i.e., the 278 RNA-seq pipelines, the
benchmark metrics, and the SEQC-benchmark datasets) can serve as guidelines for biolog-
ical and clinical researchers as well as for bioinformaticians and biotechnologists. (a) De-
pending on the gene expression application, the three metrics (i.e., accuracy, precision, and
reliability) may be used to choose a pipeline. We have associated each metric with an RNA-
seq application and listed the top-performing pipelines for each metric. The red-highlighted
component in each listed RNA-seq pipeline indicates components that frequently occur
among the top-performing pipelines for each metric. (b) Biological or clinical researchers
who want to analyze Illumina RNA-seq data (or data from similar platforms with short,
fixed-length reads) can choose an existing RNA-seq pipeline using the provided table of
278 pipelines ranked by accuracy, precision, or reliability. Bioinformaticians that are de-
veloping a new RNA-seq pipeline for Illumina data (or data from similar platforms) can
use the SEQC-benchmark datasets and benchmark metrics to evaluate the new pipeline and
assess its performance relative to the 278 pipelines. Bioinformaticians or biotechnologists
that are developing new RNA-seq protocols can first sequence the same RNA mixture sam-
ples (i.e., samples A, B, C, and D), and then evaluate associated data analysis pipelines
using the qPCR benchmark dataset and the benchmark metrics.
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most accurate pipelines. If experimental conditions limit the sample size, small variation
among replicate libraries may be important to better estimate gene expression. The pre-
cision and reliability metrics were designed to capture variation in gene expression from
different perspectives. Researchers who need small variation in gene expression across
replicate libraries for a single sample may want to weight the precision metric. Bowtie2
multi-hit and GSNAP un-splice mapping are the frequently occurring components in the
most precise pipelines. Researchers who need small within-sample variation in gene ex-
pression relative to between-sample variation may want to emphasize the reliability metric.
Again, median normalization is the frequently occurring component in the most reliable
pipelines.
In scenario 2 where researchers want to evaluate a newly developed RNA-seq pipeline
for an Illumina dataset, they may use the SEQC-benchmark dataset, qPCR benchmark
dataset, and the three metrics as follows (Figure 3.6b): (1) Analyze the SEQC-benchmark
dataset with the new RNA-seq pipeline. (2) Evaluate the new pipeline with the three met-
rics. (3) Compare the performance of the new pipeline to the 278 RNA-seq pipelines.
The 278 RNA-seq pipelines serve as a representative sample, or benchmark, of pipelines
for gene expression estimation that include both good-performing and poor-performing
pipelines.
In the third scenario, researchers who want to evaluate a new RNA-seq protocol may
use the RNA samples from the SEQC protocol (i.e., samples A, B, C, and D), the qPCR
benchmark dataset, and the three metrics as follows: (1) Sequence the RNA samples with
the new RNA-seq protocol. (2) Analyze the new dataset with new pipelines specifically de-
signed for the new RNA-seq protocol. (3) Evaluate the new pipelines and the new RNA-seq
protocol with the three metrics. Ideally, existing pipelines could be applied as fixed vari-
ables to both old and new RNA-seq protocols to attribute any changes in gene expression
estimation performance to the change in RNA-seq protocols.
It is worthwhile to mention that, in the Phase-II experiment, we set a threshold to divide
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patients in each dataset into two groups to conduct downstream predictions. This choice
balances the numbers of samples in two groups and balances the computational complexity
with the biological meaningfulness. With RNA-seq pipeline evaluation as the main focus
of this study, we want to minimize the sample size imbalance introduced bias in the down-
stream biological applications. The investigation can be improved if the choice of threshold
is more towards the real-world clinical scenarios. Moreover, we did not investigate the un-
derlying genes that contribute to the prediction. The biological and medical contexts of the
gene signature are critical for the causality assessment and clinical application in explain-
ing the disease outcome predictions. Thus, more sophisticated down-stream applications
of RNA-seq can be explored in the future to evaluate the impact of RNA-seq pipelines. In
summary, we showed that upstream RNA-seq pipelines that performed well in gene expres-
sion estimation generally performed well for downstream gene expression-based prediction
of disease outcome. Our study represents a large-scale and objective assessment of the
predictive performance of various RNA-seq pipelines and should prove useful in moving
RNA-seq-based predictive models closer to clinical applications.
3.2 Multi-Omics Integration with Cross-Modality Translation
3.2.1 Background
Breast cancer is the most common type of cancer in females worldwide. In 2018, breast
cancer constituted over 25% of about 8.5 million new cancer diagnoses in female patients
[167]. This prevalence pattern is found in the US as well, where women have over a 12%
risk of being diagnosed with breast cancer in their lives, and breast cancer cases are ex-
pected to encompass about 30% of new cancer cases. While the principal risk factor for
breast cancer is age, it is known that selected gene mutations account for about 10% of all
breast cancer cases. Research into prognostic genomic biomarkers beyond mutational sta-
tus is ongoing and may offer insights into disease mechanisms and new therapies. Breast
cancer maintains the second-highest mortality rate for cancers in females at about 13%.
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Survival rates for breast cancer are typically measured by 5-year post-diagnosis survival.
The 5-year survival rate is 90% when all stage classifications are considered. With stage
breakdown accounted for, the risk can be further stratified, as localized breast cancer sur-
vival rate is 99%, while this drops to 85% and 27% for regionally and distantly spread
cancer, respectively.
Machine learning for cancer survival analysis has attracted increasing attention in re-
cent years. Public multi-omics datasets such as The Cancer Genome Atlas (TCGA) [168]
have greatly accelerated the research for survival analysis using -omics data. The survival
analysis can be categorized into binary classification or risk regression. In a binary classi-
fication task, the patients are typically split into a short-survival group and a long-survival
group based on a predefined threshold (e.g., five years). While in risk regression studies,
each patient’s survival time is also taken into account, which is usually modeled with the
Cox proportional hazards model [169] and its extensions.
Various methods have been employed with great success in developing survival predic-
tion models with large and heterogeneous cancer datasets. For example, Zhao et al. tested
various classification algorithms to predict 5-year breast cancer survival by integrating gene
expression data with other clinical and pathological factors [170]. Authors found that all
methods tested, including gradient boosting, random forest, artificial neural networks, and
support vector machine, performed rather similarly with accuracy and area under the curve
(AUC) of .72 and .67, respectively. Importantly, this study demonstrates that classification
methods may not matter as much as the quality of the data itself [170]. Goli et al. developed
a breast cancer survival prediction model with clinical and pathological data using support
vector regression and found similar positive results [171]. This study establishes the use of
support vectors as a promising route in survival prediction with imbalanced datasets. Sim-
ilarly, Gevaert et al. integrated microarray gene expression data with clinical data using
Bayesian Networks and achieved a maximum AUC of .845 [76]. Importantly, this study
found that incorporating both data modalities improved predictions beyond either clinical
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or gene expression alone. Sun et al. created prediction models for 5-year breast cancer sur-
vival using genomic data, including gene expression, copy number alteration, methylation,
and protein expression, coupled with pathological imaging data from TCGA. The authors
utilized multiple kernel learning to enact feature-level integration of all data. Their multi-
omics model, excluding imaging data, had an AUC of 0.802± 0.032. When incorporating
the imaging data, the AUC went up slightly to 0.828± 0.034 [172]. Ma et al. have applied
factorization autoencoder to integrate gene expression, miRNA expression, DNA methyla-
tion, and protein expression for progression-free interval event prediction and achieve an
AUC of 0.74 on bladder cancer and an AUC of 0.825 on brain glioma [81].
Instead of binary classification, the survival risk regression aims to predict the expected
duration of time until one or more events happen by modeling the time to event data. The
proportional hazards model assumes the covariates are multiplicatively related to the hazard
[173]. Assuming the proportional hazards assumption holds, the Cox proportional hazards
model can estimate the effect parameters without any consideration of the hazard function
[169]. With the development of deep learning, the Cox proportional hazards model has
been extended with deep neural networks. For example, Deep Surv [174] and Cox-Time
[175] replace the linear relationship in the Cox proportional hazards model with non-linear
neural networks. In addition, L1 and L2 regularization terms have been utilized on the
network parameters to reduce the over-fitting of the models. The survival regression model
has also been applied to multi-omics data. For example, Huang et al. have developed a Cox-
proportional hazards model based multi-omics neural network for breast cancer survival
regression [82].
In our previous study [83], we have built a transnational pipeline for overall survival
prediction of breast cancer patients by decision-level integration of multi-omics data (e.g.,
gene expression, DNA methylation, miRNA expression, and copy number variations (CNVs)).
However, many right-censored samples have been discarded to enable binary classification.
In this study, we extended the work by replacing the binary survival classification with sur-
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vival risk regression to make the most of the TCGA dataset [176]. We hypothesize there
are both complementary and consensus information in the multi-omics data. To utilize
the complementary and consensus information among multi-omics data, we replace the
decision-level integration with deep learning-based feature-level integration [176]. The
remainder of the section is structured as follows: in subsection 2, we first describe the sim-
ulated two-view data from the Modified National Institute of Standards and Technology
(MNIST) database and multi-omics breast cancer (BRCA) data from the TCGA database
(referred as TCGA-BRCA hereafter). We then present the proposed methods for multi-
omics data integration by utilizing the complementary information and consensus informa-
tion among modalities. In subsection 3, we present the results of the baseline models and
proposed models on both MNIST simulated data and TCGA-BRCA multi-omics data. We
will discuss the results and conclude the work in subsection 4 and subsection 5, respec-
tively.
3.2.2 Methods
Simulated Multi-View MNIST Dataset
We simulate the multi-modality data from the Modified National Institute of Standards and
Technology (MNIST) database to validate the proposed feature-level integration network.
The MNIST database consists of 60,000 training samples and 10,000 testing samples. Each
sample in the MNIST database is a 28× 28 image of a single hand-written digit from 0 to
9. The goal is to train a multi-class classifier to predict the digit from the input image.
We simulate two-views of each hand-written digit image from the MNIST database
(Fig. 3.7A). The first view (X1) is the original image from the MNIST database, while
the second view (X2) is the corresponding rotated image (90-degree counter-clockwise
rotation). We further simulate noises for the data because the task is easy even for single-
view data. We have simulated two kinds of noises and apply them to both views of the hand-
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Figure 3.7: Simulation two-view data from MNIST database. A. Pipeline for simulation
of two-view data from the MNIST database. B. Simulated dataset S1 with random erasing
noise. C. Simulated dataset S2 with Gaussian noise.
We flatten the image to a vector with a length of 784 as the final input to deep neural
networks.
TCGA-BRCA Breast Cancer Multi-Omics Dataset
We obtain breast cancer data from the TCGA database [168], which is a public database
containing genomic data for over 20,000 paired cancer and normal samples from 33 can-
cer types. By keeping the samples that are simultaneously profiled with gene expression,
miRNA expression, DNA methylation, and CNVs, the final dataset size for survival analy-
sis is 1,060.
We summarized the four omics data modalities obtained from the TCGA-BRCA dataset
in Table 3.1 For gene expression, the number of features includes different isoforms for
each gene and some non-coding RNA transcripts. The DNA methylation beta value ranges
from 0 to 1, where a beta value of 0 means that no methylation is detected for that probe,
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Features 60,483 25,978 1,881 19,729
while a 1 means that the CpG was always methylated. For CNV features, “Gain” means
more copies of a gene than normal, while “Loss” means fewer copies of a gene than normal.
The overall pipeline for multi-omics survival analysis is presented in Fig. 3.8. Quality
control and preprocessing are essential for making sense of multi-omics data. To get rid of
the low-quality features, we remove features with missing data. For the gene expression
and miRNA expression data, we also apply a log transform log2(X + 1) to the features,
where X is the FPKM for gene expression and RPM for miRNA expression. We then
apply min-max normalization to scale all four data modalities to a range of 0 to 1. After
the quality control and normalization, we apply a stratified four-fold split of the data into a
training set (60%), validation set (15%), and a testing set (25%) in each fold.
The multi-omics data usually suffer from the “curse of dimensionality,” where the num-
ber of features is significantly larger than the number of samples. To mitigate this chal-
lenge, researchers usually apply feature selection or dimension reduction techniques to get
rid of the unrelated or redundant features, which are essential for the success of down-
stream analysis such as classification or survival analysis. For classification, supervised
univariate feature selection methods such as minimum Redundancy Maximum Relevance
(mRMR) [177] and mutual information can be used. For survival analysis, it is not straight-
forward to apply supervised feature selection, and thus various unsupervised or knowledge-
guided feature selection has been applied. For example, Huang et al. have applied gene
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TCGA-BRCA Dataset
Gene Expression DNA Methylation miRNA Expression Copy Number Variation
Preprocessing (Quality Control): Remove Missing Data
Preprocessing (Normalization): Min-Max Normalization to 0~1

























Figure 3.8: Overall pipeline for survival analysis. We obtain multi-omics data (i.e., gene
expression, DNA methylation, miRNA expression, and copy number variation) for breast
cancer patients from the TCGA-BRCA database. The multi-omics data are preprocessed
and normalized to a range of 0 to 1. We then apply four-fold cross-validation and split the
data into a training set (60%), validation set (15%), and testing set (25%) in each fold. We
train the feature selection or dimension reduction step and the survival networks using the
training set and apply them to the validation set for parameter selection and the testing set
for performance reporting.
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co-expression analysis as the dimension reduction approach [82]. This study focuses on
deep-learning-based feature-level integration. Thus, we have applied two simple feature
selection/dimension reduction approaches, principal component analysis (PCA) and unsu-
pervised variance-based feature selection. We apply PCA to the training dataset for PCA-
based dimension reduction and use the first 100 principal components (PCs) of training,
validation, and testing datasets for survival analysis. We select the top 1000 features from
the training dataset with the highest variances for unsupervised variance-based feature se-
lection. We then use these 1000 features of training, validation, and testing datasets for
survival analysis.
Single-Modality Network
For single-modality data, we propose to use an autoencoder and a task-specific network
for single-modality classification or survival analysis (Fig. 3.9). For the input data x after
feature selection, we first apply an encoder q(x) to transform the input data to a hidden
feature z, and then reconstruct the input data x̂ from the hidden feature with a decoder
p(z). We then feed the hidden feature z into a task-specific network for classification or
survival analysis.
Endpoint 1: Multi-Class Classification For the classification network c(z), we use a
fully connected network with the output dimension the same as the number of classes.
Thus, the whole network is trained with reconstruction loss Lrecon and the classification






(xn − x̂n)2 (3.1)
where N is the batch size. We use the cross-entropy loss for the classification loss:
Lclf = − log(
exp(x[class])∑C
j=1(x[j])
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Figure 3.9: Single-omics data survival analysis network. The input data x is represented
with an encoder q(x) into hidden feature z and then constructed with a decoder p(x). We
then feed the hidden feature z into a task-specific network such as multi-class classification
or survival analysis.
where C is the number of classes and j ∈ 1, ..., C. For each epoch, we first train the
encoder-decoder with the reconstruction loss Lrecon and then train the encoder and classi-
fication network with the cross-entropy loss Lclf .
The multi-class classification performance is evaluated by accuracy, weighted preci-
sion, and weighted recall. These metrics are in the range of [0, 1], and the higher the better.
We do not include AUC as a metric because we perform 10-class classification with the
simulated MNIST dataset instead of binary classification.
Endpoint 2: Survival Analysis We also use a fully connected neural network s(z) to
replace the Cox proportional hazards model for the survival analysis. The output of the
survival network s(z) is the patient’s hazard h. Based on the Cox proportional hazards










where Ci = 1 indicates the occurrence of the event for patient i, Nob is the total number
of events in the batch, and Ti and Tj are the survival time for patient i and patient j,
respectively.
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For the evaluation of the risk scores predicted by survival models, various metrics have
been developed to measure the concordance between the predicted risk scores and the ac-
tual survival time. Following the previous studies in deep-learning-based survival analysis
[82], we will evaluate the overall survival analysis performance with the concordance index
(C-index) [178]. C-index evaluates how well the survival risk we computed aligns with the
actual survival time given any two comparable pairs:
C-index = Pr{hi > hj|Ti < Tj, Ci = 1} (3.4)
Multi-Modality Integration Network
There are two principles in multi-view learning: 1) the complementary principle assumes
that each view contains information other views do not have, and we should extract the
difference from each view while preserving the common information; 2) the consensus
principle assumes that the disagreement between views upper bounds the classification
errors; thus, we should aim to maximize the agreement between views. Based on these
two principles, we have the following approaches for integrating data from multiple -omics
modalities.
1) Integrating the Complementary information: Concatenation Autoencoder (ConcatAE).
Similar to the methods discussed in Chapter 2, we use the concatenation autoencoder (Con-
catAE) to integrate the complementary information from each data modality (Fig. 3.10).
For each modality, we train an independent autoencoder and transform the input features
into a hidden space. We then concatenate the hidden features from each modality and feed
the concatenated hidden feature into the task-specific network. Compared to the single-
modality network, we have a separate reconstruction loss for each data modality. Thus, the

































Figure 3.10: Multi-omics data integration with concatenation autoencoder (ConcatAE).
The hidden features of each data modality are concatenated before feeding into the task-
specific network.






((x1,n − x̂1,n)2 + (x2,n − x̂2,n)2) (3.5)
The task-specific network training procedure remains the same, with the input becoming
the concatenation of hidden features represented from each modality.
2) Integrating the Consensus Information: Cross-Modality Autoencoder (CrossAE). We
use the cross-modality autoencoder (CrossAE) to integrate the consensus information from
each data modality (Fig. 3.11). The key idea to enable consensus representation among
modalities is using the hidden features represented from one modality to reconstruct the
input features from other modalities.
We train the framework with three steps. In the first step, we train an autoencoder for
each modality independently, as we have done in the ConcatAE model with L′recon. In the
second step, we train these encoders and decoders again with cross-modality reconstruc-
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Figure 3.11: Multi-omics data integration with cross-modality autoencoder (CrossAE). For
hidden features of each data modality, they are used to reconstruct input features of both
the original modality and other modalities. The hidden features of various modalities are
element-wise averaged before feeding into the task-specific network.
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to hidden feature z1 = q1(x1). We then use the modality 2 decoder p2(z) to reconstruct the
modality 2 input data x2 from z1, which is denoted as x̂21 = p2(z1). We can perform similar
cross-modality reconstruction from modality 2 hidden features z2 to modality 1 input data







((x1,n − x̂12,n)2 + (x2,n − x̂21,n)2) (3.6)
In the third step, we combine the hidden features from each modality with the element-
wise average and then train the encoders and task-specific network with task-specific loss
(e.g., the cross-entropy loss for classification or the negative partial log-likelihood loss for
survival regression).
We only implemented and tested the proposed integration models on two data modali-
ties, but we believe these frameworks can be naturally extended to the integration of more
than two data modalities.
Implementation and Experiments
The train-test split for cross-validation and the classification metrics are implemented with
scikit-learn [179]. The neural networks are designed and implemented with PyTorch 1.1.0.
For cancer type classification, we use a batch size of 32, an Adam optimizer with a learn-
ing rate of 0.001, and training epochs of 200. For survival analysis, we use a batch size
of 128, an Adam optimizer with a learning rate of 0.001, and training epochs of 200.
More details of the model implementation and training details can be found at Github repo
(https://github.com/tongli1210/BreastCancerSurvivalIntegration).
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Table 3.2: Multi-modality integration simulation with MNIST dataset
Random Erasing (S1) Gaussian Noise (S2)
Modalities ACC Precision Recall ACC Precision Recall
X1 0.942±0.004 0.942±0.004 0.942±0.004 0.884±0.003 0.886±0.003 0.884±0.003
X2 0.942±0.003 0.943±0.003 0.942±0.003 0.879±0.005 0.881±0.005 0.879±0.005
ConcatAE(X1+X2) 0.962±0.001 0.963±0.001 0.962±0.001 0.924±0.001 0.925±0.002 0.924±0.001
CrossAE(X1+X2) 0.962±0.002 0.962±0.002 0.962±0.002 0.933±0.002 0.933±0.002 0.933±0.002
3.2.3 Results
Multi-Modality Integration Simulation
We first test the proposed single and multi-modal integration networks on the simulated
MNIST datasets (S1 and S2). The results are presented in Table 3.2. From the results,
we can observe significant classification performance improvements after multi-modality
data integration for both random erasing dataset S1 and the Gaussian noise erasing dataset
S2. For dataset S1, we assume the model should take the complementary information
from X1 and X2 to get better performance. From the experiment results, the integration
model ConcatAE performs slightly better than the integration model CrossAE. For dataset
S2, because of the global noises for both views, we assume the model should take the
consensus information from S1 and S2 to get better performance. From the experiment
results, we observe CrossAE achieves better performance compared to ConcatAE, which
is as expected.
Multi-Modality Integration for Breast Cancer Survival Analysis
The performance of the single-omics survival analysis model is presented in Table ??.
We observe that the model achieves better performance when using PCA features than
using the high variance features for all modalities except for CNVs. Among the four -
omics data, miRNA expression is the most predictive for overall survival, followed by
DNA methylation and gene expression. Moreover, CNVs are the least predictive for breast
cancer overall survival, which is consistent with our previous findings [83]. The best single-
omics survival analysis performance is a C-index of 0.616 ± 0.057, achieved by miRNA
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PCA 0.589±0.084 0.583±0.058 0.616±0.057 0.476±0.051
Variance 0.529±0.033 0.581±0.066 0.614±0.041 0.503±0.071




















ConcatAE PCA 0.585±0.107 0.59±0.093 0.576±0.047 0.641±0.031 0.583±0.09 0.588±0.057Variance 0.507±0.036 0.53±0.052 0.524±0.038 0.625±0.023 0.586±0.068 0.603±0.04
CrossAE PCA 0.583±0.07 0.595±0.062 0.553±0.045 0.63±0.081 0.579±0.065 0.578±0.028Variance 0.511±0.027 0.558±0.054 0.53±0.033 0.605±0.059 0.576±0.026 0.613±0.066
data with PCA features.
The performance of the multi-omics integration survival analysis model is presented in
Table 3.4. Based on the results, we can observe that integration is not always beneficial for
performance. For example, the integration of gene expression and DNA methylation high
variance features can lead to a lower C-index (0.507 ± 0.036) than either gene expression
(0.529 ± 0.033) or DNA methylation (0.581 ± 0.066) alone. Among the six combina-
tions of two-omics data integration, we found the integration of DNA methylation and
miRNA expression consistently achieves a good performance. Comparing the two integra-
tion strategies, we found that the ConcatAE outperforms the CrossAE in most experiments.
Comparing the two feature selection strategies, we observed that the PCA features outper-
form high variance features in most experiments except for those involves CNV data. We
believe the PCA dimension reduction approach may not be suitable for the discrete CNV
data. Among all multi-omics integration models, the best performance (0.641 ± 0.031) is
achieved by integrating DNA methylation and miRNA expression using PCA features and
the ConcatAE model.
To evaluate the consensus among hidden features, we measure the similarity of paired
hidden features with the Euclidean distance and visualize their distributions with grouped
violin plots in Fig. 3.12. The violin plots are grouped by multi-omics modalities under
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integration (e.g., GeneExp+miRNA) and compared for the two integration methods Con-
catAE and CrossAE. For the hidden features (dimension of 10) represented from PCA
features, we can observe higher similarities (or lower Euclidean distances) for integra-
tion using CrossAE compared to those using ConcatAE (Fig. 3.12A). However, for the
hidden features (dimension of 100) represented from high variance features, the CrossAE
method will not necessarily lead to higher similarities (Fig. 3.12B). The observation is fur-
ther confirmed with grouped bar plots of the average Euclidean distances in Fig. 3.12C and
Fig. 3.12D. The results indicate that the consensus constraints imposed by CrossAE work
well for PCA features but suffer for the high variance features, which have a much higher
dimension.
To further understand the similarity among paired hidden features, we have also vi-
sualized the hidden features from the first fold of our four-fold cross-validation with the
t-Distributed Stochastic Neighbor Embedding (t-SNE). Based on the t-SNE visualization,
for hidden features represented from PCA features, we can observe better overlaps of the
CrossAE features (Green and Yellow) compared to those of the ConcatAE features (Red
and Blue), which indicate the effect of consensus constraints on multi-omics data represen-
tation. However, we observe similar patterns for the ConcatAE features (Red and Blue) and
the CrossAE features for hidden features represented from high variance features (Green
and Yellow). Thus, for the high variance features, the effect of consensus constraints by
CrossAE is not as significant.
3.2.4 Discussions
In this study, we have developed two multi-modal data integration strategies. We propose to
integrate the complementary information among modalities with ConcatAE and integrate
the consensus information using CrossAE. We have tested the proposed models on the sim-
ulated MNIST data and validated their effectiveness. We then apply the proposed models




Figure 3.12: Similarity measure with Euclidean distance of the paired hidden features. We
measure the similarity of paired hidden features with the Euclidean distance. A. Grouped
violin plots of the Euclidean distances for hidden features represented from PCA features.
B. Grouped violin plots of the Euclidean distances for hidden features represented from
high variance features. C. Grouped bar plots of the average Euclidean distances for hidden
features represented form PCA features. D. Grouped bar plots of the average Euclidean
distances for hidden features represented from high variance features. Yellow: ConcatAE.
Blue: CrossAE.
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tion and miRNA expression PCA features achieves the best performance with a C-index of
0.641± 0.031 and outperforms that of the CrossAE model (0.63± 0.081). Both integration
approaches outperform the corresponding single-modality model, which uses DNA methy-
lation or miRNA expression alone. The results indicate that these two modalities should
have both complementary and consensus information for survival prediction.
Although the ConcatAE outperforms CrossAE, we believe this does not necessarily
indicate that the complementary information is more important than the consensus infor-
mation. As we have seen in the MNIST simulated data with Gaussian noise, if the multi-
modality data are noisy and equally predictive, consensus learning can achieve higher pre-
diction performance than that of complementary learning. Moreover, the ConcatAE model
should include both the modality-invariant and modality-unique information, although nei-
ther has explicitly been maximized.
The best survival prediction performance is achieved by the integration of DNA methy-
lation and miRNA expression PCA features. However, the results are insufficient to con-
clude that DNA methylation or miRNA expression is more informative than the other
modalities. Because of the lack of biological ground truth, the model interpretation and
wet-lab validation are needed to understand the model. As a black-box model, we cannot
currently locate which biomarkers (e.g., specific genes or methylation sites) are picked by
the integration network and contribute most to the final survival prediction. Thus, as a
future direction, we propose to apply model interpretation methods to the integration net-
works and identify the biomarkers picked by the deep network. Then, these biomarkers
can be validated by literature if already discovered or by wet-lab experiments if novel. The
identification and validation of biomarkers can provide direct evidence on why some in-
tegration models outperform the others, which is essential to better understand the results
and allow translational impact on the clinical applications.
The TCGA-BRCA dataset we used for multi-omics integration is another major fac-
tor that might influence the survival prediction performance. Based on our results, the
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CNV features are the least predictive for breast cancer survival analysis. However, the
CNV features we obtained from the TCGA database are categorical (i.e., “gain”, “loss”,
or “normal”). The simplified CNV features might constrain the predictive capability of
this modality. Moreover, the gene expression data we downloaded from TCGA are nor-
malized with FPKM, and the miRNA expression data are normalized with RPM. However,
the FPKM and RPM normalization are potentially biased when comparing between sam-
ples. Although the feature extraction with RNA-seq pipelines is out of this study’s scope,
we believe the survival prediction performance can be further improved for gene expres-
sion and miRNA expression if replacing the normalization method with more sophisticated
techniques such as transcripts per million (TPM).
Although we have demonstrated the effectiveness of ConcatAE and CrossAE for multi-
omics data integration, the current study has several limitations and can be improved in the
follow-up studies. We will discuss these future directions in the model validation dataset,
generalization to larger datasets with various endpoints, and model improvements.
This study validates the proposed ConcatAE and CrossAE networks’ effectiveness with
the simulated two-view imaging data from the MNIST database. We have controlled and vi-
sualized the consensus and complementary information. Ideally, a cancer genomics dataset
with ground truth would be preferred to validate the proposed integration networks. How-
ever, based on our knowledge, there is no such golden standard multi-omics dataset de-
veloped yet. As we do not fully understand the complex interactions among multi-omics
data, it is currently infeasible to annotate all of them and develop a real-world dataset with
ground truth. We believe it is worth the biological communities to develop golden standard
multi-omics datasets to mitigate this challenge. It will be helpful to validate the consensus
and complementary principles for computational multi-omics data integration methods.
For example, with the ground-truth dataset, we can quantify the amount of complemen-
tary and consensus information among the multi-omics data. One potential direction is to
collect data for the known cross-modality pathways (e.g., DNA methylation and gene ex-
75
pression pathways), which can be used to validate the consensus principle. On the other
hand, the multi-omics data simulation, which naturally comes with ground truth, can serve
as an alternative for validation. Although some multi-omics data simulation works have
been recently developed [180, 181], they are not specifically designed to validate the in-
teractions across modalities with 1) consensus information (e.g., co-regulation pathways),
2) complementary information (e.g., modality-specific pathways/biomarkers), and 3) end-
point irrelevant information. Thus, one promising future step is to simulate multi-omics
data to validate the integration principles and corresponding methods.
One essential limitation of the current study is the relatively small sample size of the
TCGA-BRCA dataset. As a purely data-driven approach, deep learning performance is sig-
nificantly influenced by the amount of training data. However, we only have around 1,000
samples from the TCGA-BRCA dataset. One future direction is to test and improve our
model with a larger breast cancer survival dataset or combine multi-source breast cancer
survival datasets. On the other hand, besides using the TCGA database for survival anal-
ysis, we can also test the proposed integration methods’ generalizability by applying them
to other multi-omics datasets with various endpoints in follow-up studies.
There are multiple directions to improve the current multi-omics data integration model.
One primary limitation of the current framework is the feature selection step. We apply two
simple feature selection/dimension reduction methods with a focus on multi-omics data in-
tegration: unsupervised feature selection by variance ranking and unsupervised dimension
reduction by PCA. One straightforward extension is to utilize more sophisticated feature
selection methods, such as knowledge-guided feature selection. However, a more gener-
alizable future direction is integrating the feature selection or dimension reduction step
with our multi-modality network. Our current results have demonstrated that the feature-
selection or dimension-reduction steps will impact multi-modality integration performance.
To utilize the data-driven philosophy of deep learning, we can integrate the feature selection
step with the feature representation step to improve model performance.
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Secondly, a more sophisticated model to combine consensus learning and complemen-
tary learning may further improve multi-omics integration. The interactions among -omics
modalities can be complicated so that these modalities are supposed to contain both com-
plementary and consensus information. Thus, we propose to capture both complementary
and consensus information by extending the current ConcatAE framework. Instead of us-
ing one encoder for each modality, we can use two encoders or an encoder with branches
to represent both the modality-unique hidden feature and the modality-consensus feature.
The modality-unique hidden features can be learned by maximizing the divergence among
modalities, while the modality-consensus hidden features can be learned by minimizing the
divergence among modalities. Instead of cross-modality reconstruction in CrossAE, the
consensus constraints and the complementary constraints in the proposed method are both
realized by divergence optimization. Hopefully, the divergence-based consensus learning
can achieve better performance on higher dimension input data, which can overcome the
challenge CrossAE faced, as shown in Fig. 3.12B.
Besides improving the integration framework, another future direction is to improve
the survival model. This study has implemented a simple deep learning-based survival
network using the negative partial log-likelihood loss. However, we did not apply any extra
regularization to the survival model. One future work is to improve the survival network
with regularization, such as L1 loss on the network weights. We believe a more robust
survival network will further improve the multi-omics integrated survival network.
3.2.5 Conclusions
This study has investigated two multi-modal data integration strategies: ConcatAE to inte-
grate the complementary information among modalities and the CrossAE to integrate the
consensus information among modalities. We first tested the proposed models on the simu-
lated MNIST data. We validated the effectiveness of ConcatAE in integrating complemen-
tary information and CrossAE in integrating consensus information among multi-modality
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data.
We then apply the proposed models to the multi-omics breast cancer survival data ob-
tained from the TCGA-BRCA dataset. For the single-omics model, the miRNA expression
is the most predictive for breast cancer survival analysis (0.616±0.057), followed by DNA
methylation and gene expression. CNV data is the least predictive for breast cancer over-
all survival analysis. For the multi-omics model, the ConcatAE model integrating DNA
methylation and miRNA expression PCA features achieves the best performance with a
C-index of 0.641± 0.031. The CrossAE model integrating DNA methylation and miRNA
expression PCA features achieves a C-index of 0.63±0.081, which also outperforms either
DNA methylation or miRNA expression alone. We conclude that the DNA methylation
data and miRNA expression data contain both complementary and consensus information.
We can achieve improved survival analysis performance by utilizing complementary and
consensus information in the integration model. As a future direction, we believe a sophis-
ticated learning framework to integrate both consensus and complementary information in
multi-omics data can improve survival analysis performance, which is essential for person-
alized diagnosis and treatment for breast cancer patients.
3.3 Multi-Omics Integration with Divergence-based Consensus Learning
3.3.1 Background
High-throughput multi-omics data have enabled personalized diagnosis and treatments for
genetics related diseases such as cancer. However, it is extremely challenging for physi-
cians to make sense of the molecular biomarkers directly from the -omics data tsunami.
For computational scientists to integrally analyze multi-omics data, there are also a few
issues to be addressed, including “the curse of dimensionality” [182] and the multi-modal
analysis.
In multi-omics data integration, we aim to improve the diagnosis (e.g., cancer staging)
and prognosis prediction (e.g., survival analysis) by combing the information embedded
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in each modality. We categorize the multi-omics integration methods based on whether
a specific class of computational models is used. Model-agnostic approaches integrate
features from each modality directly, either by concatenating them after feature selection
[94, 79] or integrating them after decision made of each modality [83]. In model-based
approaches, models such as kernel machines, graphical models, and neural networks [80]
are needed to encode the assumptions of data. Then based on the designed models, features
are extracted for downstream tasks. Because multi-omics variations jointly impact disease
development and patient prognosis, the good data integration methods can improve the
model performance by capturing the interactions among multi-omics (e.g., gene expression
pathways) compared to single-omics methods. However, many multi-omics integration
studies in the literature can hardly exploit the full interactions among modalities and thus
result in sub-optimal performance.
Following the previous section’s investigations, because it is difficult to explore all
multi-omics interactions explicitly, we investigate how to learn the interactions implicitly
by deep neural networks with divergence-based regularization for classification and sur-
vival modeling tasks [183]. The novel contributions of this study include three parts:
1. We develop an effective end-to-end solution for integrating different modalities based
on deep neural networks. We develop a novel regularization technique to model the ob-
servation that two modalities share consensus information about the same patient. This
method can be easily extended to multiple modalities.
2. We present evidence and suggest when and how data integration should be done to
integrate different modalities of data.
3. We show the effectiveness of the new divergence-based consensus regularization by
extensive experiments on cancer types classification and cancer survival prediction, and by
visualization of the modality-invariant features after consensus learning.
In this study, we propose to integrate multi-omics data with consensus learning (Fig-











Figure 3.13: Integration of multi-omics data (e.g., gene expression, DNA methylation,
miRNA expression, and copy number variations (CNVs)) with consensus learning for im-
proved prediction performance.
the agreement between modalities. By learning modality-invariant representations with
divergence-based consensus regularization, we integrate the multi-omics data in a common
hidden space and improve the prediction of overall survival for breast cancer and ovarian
cancer patients.
3.3.2 Materials and Methods
Datasets
For cancer types classification, we collect four TCGA cancer datasets from UCSC Xena
[184] including lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC),
lung squamous cell carcinoma (LUSC), and pancreatic adenocarcinoma (PAAD) (Table 3.5).
Each cancer dataset consists of four -omics data with the same numbers of features, in-
cluding gene expression (GeneExp), DNA methylation (DnaMeth), miRNA expression
(miRNA), and copy number variations (CNVs). The GeneExp and miRNA data down-
loaded from UCSC Xena has already been log 2 transformed. We apply min-max transfor-
mation to all four -omics data and normalize features to the range (0, 1). We only keep the
samples with all four -omics data for the cancer types classification. We choose two out of
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Table 3.5: Overview of the TCGA samples for cancer types classification
Cancer Types GeneExp DneMeth miRNA CNVs # of Sampleswith All Modalities
LUAD 585 503 564 531 454
KIRC 607 483 592 536 319
LUSC 550 412 523 503 364
PAAD 182 195 183 185 177
# of features 60,483 485,577 1,881 19,729
Table 3.6: Overview of the TCGA samples for overall survival analysis







BRCA 1,222 1,234 1,207 1,106 1,061 145 8605 0
OV 379 613 499 620 362 221 5481 8
the four modalities as the input for every classification experiment configuration, and we
exhaust all six combinations for our experiments.
We collect two cancer datasets directly from the TCGA data portal for overall survival
analysis, including breast cancer (BRCA) and ovarian cancer (OV). Each cancer dataset
also consists of the GeneExp, DnaMeth, miRNA, and CNVs data along with overall sur-
vival information (Table 3.6). The number of features is 60,483 for GeneExp, 25,978 for
DnaMeth, 1,881 for miRNA, and 19,729 for CNVs in overall survival analysis. Note that
we use different DnaMeth experiment data as that in the cancer types classification. We
first apply log 2 transformation to GeneExp and miRNA data and then perform min-max
normalization to scale the features to the range (0, 1) for all -omics features. Similarly, we
only keep samples with all four -omics data for overall survival analysis.
Feature Selection and Dimension Reduction A typical -omics data set usually contains
only a few hundred samples but with millions of features. Thus, -omics data usually suffer
from the “curse of dimensionality.” Researchers typically apply various feature selection or
dimension reduction techniques to the raw- omics features to mitigate the challenge. For
example, Huang et al. apply co-expression analysis to reduce the number of gene expres-
sion and miRNA expression features [82]. EL-Manzalawy et al. utilize min-redundancy
and max-relevance for feature selection for multi-omics data [79]. This study focuses on
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integration methods and applies two simple feature selection or dimension reduction tech-
niques as we have applied in the previous section. The first method we choose is the di-
mension reduction technique principal component analysis (PCA). We apply PCA to each
-omics data and obtain the first n principal components(PCs) as the dimension-reduced
features for integration. We will call these features PCA features hereafter. To determine
the optimal numbers of PCs to keep, we apply a grid search for each task based on the
sample sizes, as the number of PCs cannot exceed the training sample sizes. We apply the
grid search for PCA features for cancer types classification with n = 50, 100, 150, 200. We
do not include the number of PCs beyond 200 as the performance improvement is marginal
for cancer types classification. For breast cancer overall survival prediction, we apply the
grid search for PCA features with n ranges from 50 to 600 with a step size of 50. For
ovarian cancer overall survival prediction, we apply the grid search for PCA features with
n = 50, 100, 150, 200, as the sample size of ovarian cancer is smaller than breast cancer.
The second method we choose is the unsupervised univariate feature selection by vari-
ance. For each -omics data, we choose the top 1000 features with the largest variances.
We will call these features high variance features hereafter. We do not apply gird search
for high variance features to determine the optimal number of features as we did for PCA
features for simplicity. The baseline models and proposed integration models are applied
to both PCA features and high variance features.
Train Test split For both cancer types classification and overall survival analysis experi-
ments, we perform a stratified four-fold cross-validation with 60% training, 15% validation,
and 25% testing data. The cancer types classification experiments are stratified with cancer
types as the label, and the overall survival analysis experiments are stratified with survival
events.
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Consensus Feature Representation Learning for Multi-Modality Data Integration
In this study, we propose to integrate multi-omics data with consensus constraints, aim-
ing to generate modality-invariant representations among various -omics data. We com-
pare the proposed network architecture’s performance with the baselines, including the
single-modality network and concatenation-based integration network with or without the
autoencoding process. The network architectures compared in this study are visualized in
Fig. 3.14. In the single-omics network (Fig. 3.14A), we use an encoder for feature repre-
sentation and a decoder for reconstruction. The represented hidden features are fed into a
task-specific network for classification or survival analysis.
In the concatenation-based multi-omics integration network (Fig. 3.14B), we have an
encoder-decoder structure for each -omics modality, the represented hidden features are
concatenated and then fed into the task-specific network (Algorithm 1). We will call this
network AutoencoderConcat. We also test the performance using the concatenation-based
network without the decoder part [82], which is called SimpleConcat.
Inspired by the integrative analysis of -omics data by dimension reduction to corre-
lated structure across modalities [185], we propose to integrate the multi-omics data with
consensus constraints (i.e., domain-invariant representations) as shown in Fig. 3.14C. With
the encoder-decoder framework for each -omics modality, we impose a divergence-based
constraint on the hidden features learned from each modality (Algorithm 2). In this study,
we tested the consensus learning with the Cosine similarity [81] and Euclidean distance,
respectively. For consensus learning with Cosine similarity, we maximize the Cosine sim-
ilarity between hidden features learned from each -omics modality. We will refer to this
framework as ConsensusCosine. We minimize the Euclidean distance between hidden fea-
tures learned from each -omics modality for consensus learning with Euclidean distance.
We will refer to this framework as ConsensusEuclidean. The learned hidden features from
concatenation-based integration and consensus-based integration are visualized with the
t-SNE plot for comparison.
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For single-modality networks, concatenation-based integration networks (SimpleCon-
cat and AutoencoderConcat), and consensus-based integration networks (ConsensusCosine
and ConsensusEuclidean), we utilize the same network structures for the shared compo-
nents. For simplicity, we have used three-layer fully connected networks with various
numbers of neurons for encoder, decoder, and task-specific networks, respectively.
Algorithm 1: Training Concatenation-Based Classification Models
Require: Multi-modal Dataset D = {(Xi = (Mi,1,Mi,2), yi)}
Require: Euc(a, b) as the Euclidean distance between vectors a, b
Initialize modality specific encoders as Enc1, Enc2
Initialize modality specific encoders as Dec1, Dec2
Initialize classification module as CLF
while Not Converged do
//Encoder-Decoder Training
Sample a batch of sample from D
loss← 0.
for each sample i in the batch do
Compute reconstructed input as M̂i,j = Decj(Encj(Mi,j), for j = 1, 2
Compute reconstruction loss recon lossi as
Euc(M̂i,1,Mi,2) + Euc(M̂i,2,Mi,2)
loss← loss+ recon lossi
Back propagate loss and update model parameters for encoders and
classification module
//Encoder-Classifier Training
Sample a batch of sample from D
loss← 0.
for each sample i in the batch do
Compute modality specific representations as hi,j = Enc1(Mi,j), for
j = 1, 2
Build joint representation as hi = Concat(hi,1, hi,2)
Compute classifiction loss clf lossi using yi and prediction ŷ = CLF (hi)
loss← loss+ clf lossi + regi
Back propagate loss and update model parameters for encoders and
classification module
return Modality specific encoders and decoders Enc1, Enc2, Dec1, Dec2, and


























































B. Multi-Omics Network by Concatenation
C. Multi-Omics Network by Divergence-Based Consensus Constraints
Figure 3.14: The network architectures for single-omics and multi-omics integration. A.
Single-omics netowrk. B. Multi-omics network by concatenation. C. Multi-omics network
by divergence-based consensus constraints
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Algorithm 2: Training Consensus-Based Classification Models
Require: Multi-modal Dataset D = {(Xi = (Mi,1,Mi,2), yi)}
Require: Euc(a, b) as the Euclidean distance between vectors a, b
Initialize modality specific encoders as Enc1, Enc2
Initialize modality specific encoders as Dec1, Dec2
Initialize classification module as CLF
while Not Converged do
//Encoder-Decoder Training
Sample a batch of sample from D
loss← 0.
for each sample i in the batch do
Compute reconstructed input as M̂i,j = Decj(Encj(Mi,j), for j = 1, 2
Compute reconstruction loss recon lossi as
Euc(M̂i,1,Mi,2) + Euc(M̂i,2,Mi,2)
loss← loss+ recon lossi
Back propagate loss and update model parameters for encoders and
classification module
//Encoder-Classifier Training
Sample a batch of sample from D
loss← 0.
for each sample i in the batch do
Compute modality specific representations as hi,j = Enc1(Mi,j), for
j = 1, 2
Build joint representation as hi = 12(hi,1 + hi,2)
Compute classifiction loss clf lossi using yi and prediction ŷ = CLF (hi)
Compute consensus regularization, for example, the Euclidean-based
regularization as regi = Euc(hi,1, hi,2)
loss← loss+ clf lossi + regi
Back propagate loss and update model parameters for encoders and
classification module
return Modality specific encoders and decoders Enc1, Enc2, Dec1, Dec2, and
classification module as CLF
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Endpoint 1: Cancer Types Classification
The first endpoint for our proposed multi-omics integration network is multi-class classifi-
cation. For this endpoint, we use a fully-connected network for classification and trained
with cross-entropy loss. The classification performance is evaluated by accuracy, precision,
recall, and area under the curve (AUC) for binary classification. For multi-class classifica-
tion, we use accuracy, weighted precision, and weighted recall as the evaluation metrics.
These metrics are in the range of [0, 1], and the higher, the better.
Endpoint 2: Survival Risk Analysis
Survival analysis aims to predict the expected duration of time until one or more events
happen by modeling the time to event data. The proportional hazards model assumes the
covariates are multiplicatively related to the hazard [173]. Assuming the proportional haz-
ards assumption holds, the Cox proportional hazards model can estimate the effect param-
eters without considering the hazard function [169]. Thus, the Cox proportional hazards
model is semi-parametric. Let Xi = Xi1, ..., Xip be covariates for subject i. The hazard
function for the Cox proportional hazards model has the form:
λ(t|Xi) = λ0(t) exp(β1Xi1 + ...+ βpXip) = λ0(t) exp(Xi · β) (3.7)
This expression gives hazards function at time t for subject i with covariate vector Xi. The











where θj = exp(Xj · β) and the summation is over the set of subjects j where the event
has not occurred before time Yi (including subject i itself). Li(β) is called a partial like-
lihood as the effect of the joint probability can be estimated without modeling the change
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of the hazard over time. Obviously 0 < Li(β) < 1. Treating the subjects as if they were















With deep learning development, the Cox proportional hazards model has been ex-
tended with deep neural networks. Cox-Time [174] and Deep Surv [175] similarly replac-
ing the linear relationship exp(Xi · β) with non-linear transformation as exp(fφ(Xi) · β),
where fφ is a neural network parametrized by φ, for example, a fully connected neural net-
work. In addition, the authors also proposed L1 and L2 regularization terms, respectively,
on the parameter φ to reduce over-fitting of the models. This study uses a fully connected
neural network for the Cox proportional hazards model with the log partial likelihood as
the loss function.
To evaluate the risk scores produced by survival models, researchers have developed
various metrics to measure the concordance between the predicted risk scores and the ac-
tual survival time. Following the previous studies in deep-learning-based survival analysis
[82], we evaluate the overall survival analysis performance with the concordance index (C-
index) [178]. C-index evaluates how well the survival risk we computed aligns with the
actual survival time, i.e., for two individuals (X1, T1), (X2, T2), C-index = Pr(λ(X2) >




The train-test split for cross-validation, the classification metrics, the t-SNE visualization
are implemented with [179]. The Kaplan-Meier plot and log-rank test are performed with
lifelines [186]. The neural networks are designed and implemented with PyTorch 1.1.0.
For cancer types classification, we use a batch size of 8, Adam optimizer with a learning
rate of 0.001, and training epochs of 200. The test performance is based on the models
with the best validation performances. For survival analysis, we use a batch size of 128,
Adam optimizer with a learning rate of 0.001, and training epochs of 200. As we observed
an over-fitting for models with the best validation performance, the test performance is
based on the models until the end of training (200 epochs). More details of the model




We perform cancer types classification using four TCGA datasets (LUAD, KIRC, LUSC,
and PAAD) with six binary classifications and one four-class classification. The binary
classification is evaluated with accuracy, precision, recall, and AUC. The four-class clas-
sification is evaluated with accuracy, precision, and recall. For each cancer-types classi-
fication task, we perform PCA feature reduction with a grid search of the number of PCs
from 50 to 200 with a step size of 50. The percentage of variances explained by the PCs are
compared for each classification task and train-test split. Based on the results, we observe
that the first 50 PCs can explain about 70%, 90%, 80%, 70% of variances for GeneExp,
DnaMeth, miRNA, and CNV, respectively.
We perform cancer types classification using two of the proposed frameworks Autoen-
coderConcat and ConsensusEuclidean. The classification results using various numbers of
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PCA features and high variance features are compared. Furthermore, we visualize the ac-
curacy of integration-based cancer types classification for some selected experiments using
radar plots in Fig. 3.15. For single-omics binary classification, GeneExp, DnaMeth, and
miRNA achieve similar performance and significantly outperform CNV. For multi-omics
binary classification, the accuracy for both integration frameworks AutoencoderConcat or
ConsensusEuclidean is very high except for LUAD vs. LUSC. Since LUAD and LUSC
are both lung cancers, we suspect the separation of LUAD vs. LUSC is harder than the
other binary classification tasks, which also explains the performance drop for four-class
classification that includes both LUAD and LUSC. Comparing the two multi-omics inte-
gration approaches, we find that the AutoencoderConcat consistently outperforms the Con-
sensusEuclidean integration when using PCA features. In contrast, the AutoencoderConcat
integration consistently outperforms the ConsensusEuclidean integration when using high
variance features (Fig. 3.15).
Cancer Overall Survival Analysis
Evaluation of Overall Survival Analysis using C-index Like the cancer types classifica-
tion task, we perform PCA feature reduction with a grid search of the number of PCs for
breast cancer and ovarian cancer overall survival prediction. The percentages of variances
explained by the PCs are compared for various modalities and train-test splits for breast
cancer. Based on the results, we observe that the first 50 PCs can explain about 72%,
92%, 82%, 64% of variances for GeneExp, DnaMeth, miRNA, and CNV, respectively. The
percentages of variances explained by the PCs are compared for various modalities and
train-test splits for ovarian cancer. Based on the results, we observe that the first 50 PCs
can explain about 72%, 91%, 84%, 71% of variances for GeneExp, DnaMeth, miRNA, and
CNV, respectively.
We evaluate the overall survival analysis performance with PCA features and high vari-




Figure 3.15: Radar plots of the accuracy for cancer types classification using Autoen-
coderConcat framework and ConsensusEuclidean framework for integration. A. LUAD
vs. KIRC binary classification using the top 100 PCA features. B. LUAD vs. KIRC binary
classification using the high variance features. C. LUAD vs. KIRC vs. LUSC vs. PAAD
four-class classification using the top PCA features. D. LUAD vs. KIRC vs. LUSC vs.
PAAD four-class classification using the high variance features. Blue lines: Autoencoder-
Concat. Yellow lines: ConsensusEuclidean.
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Table 3.7: BRCA Overall Survival (OS) Analysis C-Index with Single-Omics
Features GE DM mR CNV
PCA 300 0.585±0.065 0.591±0.064 0.629±0.089 0.496±0.051
High Variance 0.529±0.033 0.581±0.066 0.614±0.041 0.503±0.071
cancer (BRCA) survival analysis, the best performance for PCA features is achieved with
300 PCs. Thus, we select the results using 300 PCs in Table 3.7 for single-omics ex-
periments and Table 3.8 for multi-omics experiments. For ovarian cancer (OV) survival
analysis, the best performance for PCA features is achieved with 50 PCs. Thus, we se-
lect the results using 50 PCs in Table 3.9 for single-omics experiments and Table 3.10 for
multi-omics experiments.
From the tables, we can observe that overall survival analysis’s performance improves
after integrating multi-omics data with either PCA features or high variance features. For
BRCA survival analysis, the concatenation-based integration outperforms consensus-based
integration in some -omics combinations while consensus-based integration outperforms
concatenation-based integration in the other -omics combinations. The consensus-based
integration ConsensusCosine using PCA features of DnaMeth and miRNA achieves the
best performance (0.671 ± 0.046). The consensus-based integration ConsensusEuclidean
using PCA features of miRNA and CNV achieves a similar performance (0.667± 0.073).
For OV survival analysis, we also observed that the concatenation-based integration
outperforms consensus-based integration in some -omics combinations while consensus-
based integration outperforms concatenation-based integration in the other -omics combi-
nations. The concatenation-based integration AutoencoderConcat using PCA features of
miRNA and CNV achieves the best performance (0.571± 0.036). We have also compared





Figure 3.16: Radar plot of the C-Index for overall survival analysis using concatenation
and consensus based multi-omics integration. A. Breast cancer (BRCA) overall survival
(OS) C-index with Top 300 PCA features. B. Breast cancer (BRCA) overall survival (OS)
C-index with high variance features. C. Ovarian cancer (OV) overall survival (OS) C-index
with Top 50 PCA features. D. Ovarian cancer (OV) overall survival (OS) C-index with high
variance features. Green lines: SimpleConcat. Blue lines: AutoencoderConcat. Magenta
lines: ConsensusCosine. Yellow lines: ConsensusEuclidean.
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Table 3.8: BRCA Overall Survival (OS) Analysis C-Index with Multi-Omics
Features Methods GE+DM GE+mR GE+CNV DM+mR DM+CNV mR+CNV
PCA 300
SimpleConcat 0.596±0.054 0.644±0.057 0.583±0.066 0.651±0.055 0.562±0.057 0.608±0.039
AutoencoderConcat 0.607±0.073 0.609±0.053 0.588±0.105 0.655±0.062 0.552±0.061 0.627±0.062
ConsensusCosine 0.558±0.081 0.609±0.078 0.571±0.054 0.671±0.046 0.565±0.024 0.609±0.056
ConsensusEuclidean 0.581±0.057 0.591±0.115 0.52±0.025 0.637±0.073 0.618±0.086 0.667±0.073
High Variance
SimpleConcat 0.524±0.024 0.525±0.04 0.558±0.019 0.633±0.042 0.577±0.04 0.609±0.054
AutoencoderConcat 0.507±0.036 0.53±0.052 0.524±0.038 0.625±0.023 0.586±0.068 0.603±0.04
ConsensusCosine 0.532±0.017 0.543±0.011 0.494±0.052 0.61±0.068 0.557±0.034 0.61±0.056
ConsensusEuclidean 0.528±0.018 0.606±0.041 0.532±0.02 0.626±0.056 0.554±0.024 0.585±0.049
Table 3.9: OV Overall Survival (OS) Analysis C-Index with Single-Omics
Features GE DM mR CNV
PCA 50 0.504±0.016 0.488±0.046 0.549±0.037 0.523±0.037
High Variance 0.49±0.024 0.524±0.026 0.506±0.046 0.497±0.03
Visualization of Risk Prediction with Kaplan-Meier Plot
Besides the C-index for evaluating survival analysis, we also perform the Kaplan-Meier
plot with the log-rank test to visualize the hazard prediction. We group the testing samples
into the low-risk and high-risk groups by the median of all predicted hazards. If a testing
sample’s predicted hazard is lower than the median hazard of all testing samples, it will
be assigned to the low-risk group; otherwise, it will be assigned to the high-risk group.
We visualize the two groups with Kaplan-Meier curves and test the separation of these
two groups with the log-rank test. Fig. 3.17 presents the Kaplan-Meier plot of breast can-
cer(BRCA) overall survival (OS) analysis using the integration of the top 300 PCA features
of DnaMeth and miRNA. From this Kaplan-Meier plot, we observe that all four integra-
tion methods are able to achieve a good separation of the low-risk and high-risk groups.
Fig. 3.18 presents the Kaplan-Meier plot of breast cancer (BRCA) overall survival (OS)
Table 3.10: OV Overall Survival (OS) Analysis C-Index with Multi-Omics
Features Methods GE+DM GE+mR GE+CNV DM+mR DM+CNV mR+CNV
PCA 50
SimpleConcat 0.519±0.034 0.505±0.033 0.548±0.015 0.529±0.075 0.517±0.044 0.545±0.057
AutoencoderConcat 0.462±0.027 0.556±0.059 0.503±0.027 0.513±0.014 0.489±0.074 0.571±0.036
ConsensusCosine 0.497±0.011 0.507±0.043 0.553±0.053 0.497±0.053 0.535±0.037 0.533±0.036
ConsensusEuclidean 0.496±0.039 0.548±0.025 0.512±0.026 0.485±0.047 0.508±0.026 0.54±0.067
High Variance
SimpleConcat 0.525±0.034 0.541±0.053 0.526±0.036 0.535±0.017 0.524±0.021 0.504±0.051
AutoencoderConcat 0.534±0.032 0.523±0.024 0.525±0.016 0.518±0.03 0.506±0.031 0.519±0.058
ConsensusCosine 0.547±0.045 0.545±0.027 0.54±0.052 0.542±0.015 0.545±0.068 0.483±0.035
ConsensusEuclidean 0.541±0.053 0.549±0.053 0.51±0.066 0.53±0.038 0.513±0.073 0.475±0.032
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analysis using the integration of the top 300 PCA features of miRNA and CNV. From this
Kaplan-Meier plot, we can observe the ConsensusEuclidean achieves the best low-risk and
high-risk group separation, while the SimpleConcat has the worst low-risk and high-risk
group separation. Additional Kaplan-Meier plots can be found in [183].
Visualization of the Hidden Features with t-SNE and Scatter Plot
We use t-SNE to visualize the hidden features learned by four multi-omics integration
methods (concatenation-based: SimpleConcat and AutoencoderConcat; consensus-based:
ConsensusCosine and ConsensusEuclidean). After reducing the dimensions of the hidden
features to two, we visualize the decomposed hidden features with scatter plots (Fig. 3.19.
We illustrate the integration of DnaMeth and miRNA in Fig. 3.19A and the integration
of miRNA and CNV in Fig. 3.19B. From the scatter plots, we observe that the multi-
omics hidden features learned by consensus-based integration align better compared to that
of concatenation-based integration. The results demonstrate that the Cosine-similarity-
based consensus learning (ConsensusCosine) and the Euclidean-based consensus learning
(ConsensusEuclidean) improve the cross-modality alignment for multi-omics data, which
contributes the performance improvements on survival analysis.
3.3.4 Discussions
If using 1,000 high variance features in the cancer types classification, consensus-based in-
tegration consistently outperforms concatenation-based integration. While if using top 100
PCA features, concatenation-based integration consistently outperforms the consensus-
based integration. Because the consensus-based integration is based on the mutual in-
formation co-existing in multiple -omics modalities, when features are more compressed
as in PCA features, the concatenation strategy works better. Thus, mutual information
among modalities is essential when applying consensus-based integration. For example,






Figure 3.17: Kaplan-Meier plot of the breast cancer (BRCA) overall survival (OS) predic-
tion by integrating the top 300 PCA features of DnaMeth and miRNA on train-test split
fold 1. A. Distribution of predicted hazards with SimpleConcat. B. Kaplan-Meier plot
of OS prediction with SimpleConcat. C. Distribution of predicted hazards with Autoen-
coderConcat. D. Kaplan-Meier plot of OS prediction with AutoencoderConcat. E. Distri-
bution of predicted hazards with ConsensusCosine. F. Kaplan-Meier plot of OS prediction
with ConsensusCosine. G. Distribution of predicted hazards with ConsensusEuclidean. H.






Figure 3.18: Kaplan-Meier plot of the breast cancer(BRCA) overall survival (OS) predic-
tion by integrating the top 300 PCA features of miRNA and CNV on train-test split fold
2. A. Distribution of predicted hazards with SimpleConcat. B. Kaplan-Meier plot of OS
prediction with SimpleConcat. C. Distribution of predicted hazards with AutoencoderCon-
cat. D. Kaplan-Meier plot of OS prediction with AutoencoderConcat. E. Distribution of
predicted hazards with ConsensusCosine. F. Kaplan-Meier plot of OS prediction with Con-
sensusCosine. G. Distribution of predicted hazards with ConsensusEuclidean. H. Kaplan-
Meier plot of OS prediction with ConsensusEuclidean.
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A B
Figure 3.19: Scatter Plot of the hidden features generated for breast cancer (BRCA) overall
survival (OS) analysis after t-SNE decomposition. A. t-SNE scatter plot for hidden features
represented from the top 300 PCA features of DnaMeth and miRNA (cross-validation fold
1). B. t-SNE scatter plot for hidden features represented from the top 300 PCA features of
miRNA and CNV (cross-validation fold 2).
ing), consensus learning may not be a good option. In overall survival prediction, both
the concatenation-based and consensus-based integration models consistently outperform
the single-modality models. However, the rank of their performance varies with different
choices of modality combinations. A future study is needed to understand when consensus
works better than concatenation in survival prediction.
In this study, we have developed a multi-omics data integration method by divergence-
based modality-invariant representation. To impose consensus constraints among modal-
ities, we maximize the Cosine similarity (ConsensusCosine) or minimize the Euclidean
distances (ConsensusEucldiean) on the features represented from each -omics modality.
The first future direction is to replace the Cosine similarity or Euclidean distance with
other divergence criteria such as Wasserstein distance or adopt adversarial learning for
modality-invariant representation instead of the predefined divergence metrics. That is to
differentiate features represented from various modalities by training the discriminator and
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the modality-specific encoders in an adversarial fashion.
The second future direction is to integrate the feature selection or dimension reduction
step with our multi-modality network. We have currently utilized variance for feature se-
lection and PCA for dimension reduction, respectively, which have shown influences on
multi-modality integration performance. As deep learning can offer fully data-driven anal-
ysis, we can integrate the feature selection step with the modality-invariant representation
step to improve the overall model performance. However, to enable such automatic feature
engineering, one bottleneck could be the amount of data available for training.
Another future direction is to utilize multi-task learning with multi-view learning. In
this study, we train encoders for each -omics modality (e.g., GeneExp, DnaMeth, miRNA,
and CNV) independently when applying to various endpoints (e.g., cancer types classifica-
tion and survival analysis). However, for encoders of a specific modality (e.g., GeneExp),
they transform raw -omics features to hidden spaces with the same dimensions, despite that
hidden features might be used for various cancer types (BRCA vs. OV) and prediction
tasks (e.g., cancer types classification vs. survival analysis). Thus, we will apply multi-
mask learning to combine the training of these encoders and obtain potential performance
improvements.
3.3.5 Conclusions
This study presented an effective end-to-end solution for integrating multi-omics data based
on deep neural networks. We developed a new divergence-based consensus regularization
techniques to capture the consensus information among modalities to improve prediction
performance. Although we only tested this new algorithm for a two-modality integration
scenario with two divergence metrics (i.e., Cosine similarity and Euclidean distance), this
novel method can be easily extended to multiple modalities and advanced divergence met-
rics. Through our analysis, we demonstrated why and how to integrate different modalities
of data. Our experiment results validated the effectiveness of our new method for both can-
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cer types classification and survival prediction. In the visualization of features, we observed




SEMI-SUPERVISED LEARNING FOR MEDICAL IMAGING INFORMATICS
4.1 Introduction
The computer-aided diagnosis (CAD) system utilizes digital imaging processing and ma-
chine learning for medical imaging analytics. CAD systems aim to help doctors interpret
medical images to speed up the diagnosis and reduce human biases. A typical CAD sys-
tem consists of image quality control, feature extraction, predictive modeling, and model
visualization, which enables automatic decision making with reliable and reproducible per-
formance [35]. With the ability to quantitatively represent medical images, the CAD system
helps detect rare events and subtle changes that may be extremely challenging for human
observers. Thus, researchers have developed CAD systems for multiple imaging modali-
ties including CT [187], MRI [188], and whole-slide images [189], which have significantly
improved the diagnosis of various diseases.
Optical Endomicroscopy (OE) is a newly emerged endoscopic imaging based on con-
focal microscopy, spectroscopy-based imaging, or optical coherence tomography (OCT)
[190]. By combining endoscopy and microscopy, OE can function as ‘optical biopsies,’
which enables real-time in situ biopsy instead of the conventional biopsy and histopathol-
ogy. Using an OE technique, the physician can make real-time clinical decisions about the
grade of dysplasia, if present, and potentially treat the patient during the same endoscopic
session. Thus, this novel technique can significantly decrease the waiting time from the
time of diagnosis (TOD) to time for endoscopic treatment (TET). The newly emerged OE
technique provides gastrointestinal endoscopists the opportunity to evaluate the esophageal
lining and mucosa in real-time through optical biopsy. Compared with the conventional
biopsy through endoscope plus microscopic examination afterward, OE can improve clini-
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cal care for patients with gastrointestinal conditions like Barret’s esophagus (BE). BE is a
disorder defined as abnormal changes from normal squamous epithelium to the columnar
epithelium. The abnormal changes usually happen in the lower portion of the esophagus
[191]. BE is a well-known risk factor for esophageal adenocarcinoma (EAC). Once BE
is diagnosed, doctors will perform a biopsy and use the histologic severity of the targeted
BE tissue to determine the cancer prevention surveillance intervals and treatment recom-
mendations. With the limited amount of tissue collected during a biopsy and the time de-
lay between biopsy and actual diagnosis, OE is a promising novel technique for real-time
diagnosis using optical biopsy. Clinical trials have demonstrated that OE could achieve
improved clinical care quality for patients with BE [192, 193, 194]. However, a large num-
ber of microscopic images are generated during an OE session. Human examination of all
microscopic images in real-time through an OE session can be demanding and prone to
errors. Thus, a fast and reliable CAD system to automatically process these microscopic
images is essential to enable real-time diagnosis for BE patients using OE techniques.
To build a reliable CAD system, we typically need substantial labeled training data to
select the optimal feature subsets and train robust classification models through supervised
learning. However, accumulating a large labeled dataset for OE images can be expensive
and time-consuming, and there are no public OE datasets available yet. On the other hand,
it is relatively easy to collect a significant number of unlabeled images through each OE
session. Thus, considering the lack of labeled OE images and the easy access to unlabeled
OE images, we propose to improve the classification of OE images by utilizing the un-
labeled images through semi-supervised learning. In the previous study, we have applied
handcrafted feature extraction and label propagation methods for semi-supervised learning
[195]. With the rapid development of deep learning and their massive success in natural
image processing, we propose to improve our previous method by exploiting the convolu-
tional autoencoders (CAE) and developing a semi-supervised deep neural network, CAES-
Net, for improving the multi-class classification of BE. With extensive experiments on the
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Figure 4.1: Example Images of three types of commercial OE systems. Left: Endoscope-
based confocal laser endomicroscopy (eCLE). Middle: Probe-based confocal laser endomi-
croscopy (pCLE). Right: Volumetric laser endomicroscopy (VLE).
OE dataset collected at Emory University, we have demonstrated the superior performance
of our semi-supervised CAESNet compared with all baselines [196].
4.2 Related Works
4.2.1 Optical Endomicroscopy
Optical endomicroscopy (OE) is a novel optical technology integrating endoscopy with
microscopy for in situ diagnosis. It enables real-time diagnosis and treatment, in contrast
to the delay in treatment due to the inherent time needed to obtain a final diagnosis by
histopathology.
Currently, three types of commercial OE systems are available for clinical use: endoscope-
based confocal laser endomicroscopy (eCLE), probe-based confocal laser endomicroscopy
(pCLE), and volumetric laser endomicroscopy (VLE) (Figure 4.1) [190], which have been
developed and approved in 2004, 2006, and 2013 respectively. Table 4.1 compares specifi-
cations of the three technologies. They are significantly different in resolution, acquisition
position, acquisition speed, and microscopic imaging presentation, and we refer the readers
to these papers for detailed comparison [190, 197, 198, 199]. As clinical trials suggest that
eCLE has better performance than pCLE in the diagnosis of esophageal diseases [200], we
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Model Pentax ISC 1000 Nvision VLE
Data Format Surface Images Surface image video Helical scan video
Axial
Information Multiple z-planes Single z-plane Multiple z-planes
Axial
Resolution 7 µm NA 7 µm
Lateral
Resolution 0.7 µm 3.5 µm NA
Z-depth 0 – 250 µm 60 µm 0 – 3000 µm
Format Size 500×500 600 µm diameter 6 cm scanacquisition length
Image Size 1024×1024 580×576 NA





focus on developing a semi-supervised classification method for eCLE images. We believe
this method can be readily generalized to other OE modalities.
4.2.2 Barret’s Esophagus
Barrett esophagus (BE), a well-known risk factor for esophageal adenocarcinoma (EAC)
[201], is characterized by the abnormal changes from normal squamous epithelium to the
columnar epithelium at the lower portion of the esophagus. The population incidence of
EAC in the United States has an estimated rise of 300% to 350% since the 1970s [202,
203], making up 60% of the new esophageal cancer diagnosis in the U.S. in 2009 [204],
with only a 5-year survival rate of 15 to 20% [205]. The progression from BE to adenocarci-
noma involves multiple stages: nondysplastic BE, low-grade dysplasia (LGD), high-grade
dysplasia (HGD), and finally adenocarcinoma [206].
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The impact of BE on the mortality from EAC is still unclear, which makes directly
screening for BE controversial [207]. Thus, physicians identify patients with BE through
either subjective selectively screening [208] or an upper endoscopy performed for an unre-
lated reason. The rapid development of OE may provide another mechanism to help detect
the neoplastic changes earlier than conventional endoscopy and improve the efficiency of
cancer surveillance [200]].
4.2.3 Computer-Aided Diagnosis for BE Classification
The CAD-based BE classification using OE has become an emerging field of research due
to the rapidly increasing population incidence of EAC. It can realize real-time diagnosis,
improve the patients’ prognosis by early detection, and reduce the physicians’ workload.
Conventional CAD pipeline includes image quality control, feature extraction, predictive
modeling, and model visualization. For example, Grisan et al. applied a support vector
machine to identify gastric metaplasia vs. intestinal metaplasia using rotation invariant
local binary pattern features [209]. Veronese et al. improved the approach via a two-
stage classification pipeline [210], and Ghatwary et al. applied image enhancement before
feature extraction for increased overall accuracy [211].
More recently, deep learning has also been applied to the classification of BE using OE
images. For example, Mendel et al. have implemented deep convolutional neural networks
(CNN) for binary classification of patients into EAC and non-EAC, realizing a sensitivity
of 0.94 and a specificity of 0.88 with leave-one-out cross-validation [212]. Hong et al. have
also applied CNN for three-class classification for BE and neoplasia using endomicroscopic
images with an accuracy of 80.77% [213].
However, the CAD system’s performance and generalization capability are still largely
constrained by the scarcity of annotated images. Besides collecting more annotated data,
researchers incorporate unsupervised, semi-supervised, and weakly supervised learning to
make the most of the data available.
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One major application of semi-supervised learning is image segmentation. Papandreou
et al. are among the first in studying weakly- and semi-supervised learning for semantic
image segmentation [214]. The authors designed an expectation-maximization (EM) algo-
rithm for iteratively updating the prediction for pixel-level annotations and the parameters
of segmentation neural networks. Jia et al. approached the weakly-supervised segmenta-
tion with multiple instance learning by aggregating the pixel-level annotations and designed
a constrained optimization process when additional supervision information is available
[215]. More recently, Li et al. studied weakly-supervised segmentation for the prostate
cancer pathological images by utilizing the prior knowledge about the epithelium-stroma
distribution [216].
Besides image segmentation, semi-supervised learning has also been applied for im-
age classification. For example, our prior work applies semi-supervised learning to eCLE
images by propagating labels to unlabeled images [195]. However, handcrafted feature
extraction is one major bottleneck for further performance improvement. The CAE’s un-
supervised nature makes it a popular choice for automated image feature extraction [217],
which can naturally utilize the unlabeled data for improved feature representation. Thus,
in this study, we adopt the CAE to build a semi-supervised deep neural network called
CAESNet for improving the classification of BE status using OE images.
4.3 Methods
4.3.1 Data
The data we used were images collected from patients undergoing endoscope-based Con-
focal Laser Endomicroscopy (eCLE) procedures for BE at Emory Hospital. The dataset
consists of 429 images labeled as one of the nine classes by an expert gastrointestinal en-
domicroscopist and 2,826 unlabeled images for semi-supervised learning. The statistics of
these images are summarized in Table 4.2. Example images for each class are shown in
Figure 4.2.
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Table 4.2: Statistics of the BE Dataset
Sub-Classes Number of Images
Low Risk
Squamous (Sq) 41
Intestinal Metaplasia (IntMet) 153
Low Grade Dysplasia (LowG) 23
High Risk High Grade Dysplasia (HighG) 4
Intraepithelial Carcinoma (IntraCar) 43
Other
Duodenum (Duod) 48
Gastric Antrum (GasAnt) 60
Gastric Body (GasBody) 28
Gastric Cardia (GasCard) 29
Total 429
Figure 4.2: Example images of the eCLE dataset we used in this paper. The images can
be classified into nine categories including squamous (Sq), Intestinal metaplasia (IneMet),
Low grade dysplasia (lowG), High grade dysplasia (HighG), Intraepithelial carcinoma (In-
traCar), Duodenum (Duod), Gastric antrum (GasAnt), Gastric Cardia (GasCard).
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Figure 4.3: Visualization of the proposed convolutional autoencoders based semi-
supervised learning model CAESNet. The original images are first encoded into hidden
codes through five layers of convolutional layers with a filter size of 4×4 and a stride of 2.
The hidden codes can be either feed into fully connected layers for classification or can be
feed into the five layers of deconvolutional layers for decoding into original images.
4.3.2 Image Preprocessing and Data Augmentation
The original size of our eCLE images is 1024×1024. Because of the limited number of
training data, we apply image augmentation to increase the number of instances for train-
ing, which is expected to improve image reconstruction and classification performance. We
apply a data augmentation for each batch of training images consisting of random rotation,
zooming-in, and flipping. The augmented images are then scaled into a smaller size of
256×256 to reduce the number of parameters. More details of the image preprocessing
and augmentation can be found in [196].
4.3.3 CAESNet: Stacked Convolutional Autoencoders (CAEs) for Semi-supervised Learning
The structure of CAESNet is shown in Figure 4.3, which consists of a stacked convolutional
autoencoder for unsupervised feature representation and fully connected layers for image
classification. The encoder consists of five convolution layers, each with a filter of size 4
and stride 2, resulting in encoded hidden codes of size 8×8. Similarly, the decoder consists
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of five deconvolution (transposed convolution) layers with the same filter size and stride as
that of encoders. The depth of each layer of the encoder is 16, 32, 64, 128, and 100, re-
spectively, with the last layer as the bottleneck layer. The bottleneck layer with dimension
8×8×100 is first flattened into a vector of length 6,400 and then connected to the second
fully connected layers through a ReLU activation function, a dropout layer, and a batch
normalization layer. Finally, the label is predicted from the second fully connected layer
with a soft-max function. The dropout layer is applied during the training stage and turned
off during the test stage. There are two loss functions in this network, namely reconstruc-
tion loss and classification loss. We use the reconstruction loss in the unsupervised stage to
train the encoder-decoder with both labeled and unlabeled images. In the supervised stage,
we use the classification loss to train the encoder-classifier with only labeled images. The
reconstruction loss lR is a measure of the differences between the input images and the










(xij − x̂ij)2 (4.1)
, where M is the number of images in the batch, N is the number of pixels of each input
image, xij is the original value of the jth pixel of the ith image, and x̂ij is the value of the
jth pixel of the ith reconstructed image.
We use the cross-entropy function as classification loss lC to measure of the differences






(yi · log(ŷi)) (4.2)
, where M is the number of images in the batch, yi is the real label of the ith image in the
batch, and ŷi is the predicted probability of the ith image. The yi is a vector of one-hot
coded labels, which equals 1 for the real label and 0 for other labels.
We construct four models utilizing all or parts of this network structure with or without
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Table 4.3: The Major Components of Four Models
Components Loss Function Train Set Endpoints
Model 1 Encoder, Decoder Reconstruction Loss Labeled/Unlabeled Reconstruction
Model 2 Encoder,Fully Connected Classification Loss Labeled Classification
Model 3 Encoder, Decoder,Fully Connected
Reconstruction Loss









the unlabeled images. The major components of these four models are summarized in
Table 4.3.




zi = Encoderθ(xi) ∀xi ∈ D





















zi = Encoderθ(xi) ∀xi ∈ D
ŷi = FCφ(zi) ∀zi





n lC(xi, yi) ∀{xi, yi} ∈ D




(θ, φ) ∈ (θ, φ) + Γ(gθ, gφ)
In model 1, we implemented a stacked CAE, which is an unsupervised feature repre-
sentation network. Each input image is encoded by an encoder with five convolution layers
into hidden codes. The input images are then reconstructed by a decoder with five deconvo-
lution layers (transposed convolution layers) from the hidden codes. The network is trained
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Def Model 2({LabeledImages, Labels}):
while modelConverged() do
supervisedTrain({LabeledImages, Labels})









by minimizing reconstruction loss (Algorithm 3 unsupervisedTrain).
In model 2, we use only the stacked convolutional encoders and the fully connected
layers for image classification, which is a standard implementation for image classifica-
tion. Each input image is firstly encoded and then classified into multiple categories. The
network is trained by minimizing the classification loss using only the labeled images (Al-
gorithm 3 supervisedTrain).
In model 3, we use both the stacked CAE for image reconstruction and the fully con-
nected layers for image classification, but only using the labeled images. In each training
step, we first update the encoder and decoder by reconstruction loss, then we update the en-
coder and fully connected layers by classification loss. All images are firstly encoded into
hidden codes. After encoding, we reconstruct the input images and update the encoder and
decoder by taking the gradient of reconstruction loss. Then, we use the updated encoder to
regenerate the hidden codes and pass them through fully connected layers for image clas-
sification. We update the encoder and fully connected layers by taking the gradient of the
classification loss (Algorithm 4 Model 3).
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In model 4 (CAESNet), we use the same structure as model 3 but utilize both labeled
and unlabeled images for training. For each image, if it is labeled, we first update the en-
coder and decoder, then update the encoder and fully connected layers; on the other hand,
if it is unlabeled, we only update the encoder and decoder by minimizing the reconstruc-
tion loss (Algorithm 4 Model 4). The implementation details of model 4 are presented in
Supplementary Note 2.
4.3.4 Model Evaluation and Classification Metrics
The three classification pipelines are evaluated using stratified four-fold cross-validation.
We split the labeled data into training, validation, and test datasets in each fold of the cross-
validation. We initiate the weights of our networks with multiple random seeds and select
the best model based on the classification loss on the validation set. Data augmentation has
been applied only on the training datasets. To enable statistical test, we repeat the four-fold
cross-validation three times.
We evaluate the multi-class classification results using four metrics, namely accuracy,
precision, F1 score, and Cohen Kappa score. We do not include recall since it is the same as
accuracy for multi-class classification if we weighted the recall by the number of samples
in each class.
4.3.5 Experiment Configuration
We run all data processing pipelines and models on a single server with multiple CPU cores
and two NVIDIA Tesla K80 GPUs. The image augmentation is implemented with Python
Library Augmentor [218] with random rotation, scaling, and flipping. The CAESNet and
the baseline deep learning models are implemented with PyTorch. The classification results
are evaluated with scikit-learn [179]. For the training of semi-supervised networks, we use
a batch size of 20, epochs of 200, and a learning rate of 0.0002. We apply different depths
(i.e., 16, 32, and 64) to each convolutional layer to see the influence on the classification
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Figure 4.4: The original images (blue rectangle) and the corresponding reconstructed im-
ages (red rectangle) by autoencoders in three different models. Model 1: an autoencoder
using labeled images. Model 3: an autoencoder + a classifier using only labeled images.
Model 4 (CAESNet): an autoencoder + a classifier using both labeled and unlabeled im-
ages. Model 1 and model 4 (CAESNet) achieve better reconstruction results compared to
those of model 3.
and reconstruction performance.
4.4 Results
4.4.1 Improved Image Reconstruction Performance by Extra Training with Unlabeled
Images
The image reconstruction quality increases when increasing the number of training images.
Figure 4.4 shows the original images and the reconstructed images from the test set for
models 1, 3, and 4. The reconstructed image quality of model 3 is the worst compared to
model 1 and model 4. However, model 4 can achieve similar reconstruction performance
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Table 4.4: Classification Performance of Models with Various Implementations




LP 0.734±0.0175 0.763±0.0479 0.674±0.0269 0.642±0.0241
Rand. LP(20) 0.652±0.0465 0.709±0.0277 0.584±0.0453 0.528±0.0741
Rand. LP(90) 0.686±0.0318 0.702±0.0519 0.624±0.0394 0.577±0.0477
Model 2
(Supervised)
Depth 16 0.679±0.0375 0.67±0.0623 0.652±0.046 0.6±0.0491
Depth 32 0.683±0.0368 0.671±0.0661 0.656±0.0458 0.6±0.0486
Depth 64 0.667±0.0431 0.628±0.0784 0.626±0.0554 0.572±0.0601
Model 3
(Supervised)
Depth 16 0.787±0.0369 0.804±0.0376 0.774±0.0354 0.733±0.0439
Depth 32 0.808±0.045 0.819±0.034 0.798±0.0448 0.761±0.052




Depth 16 0.784±0.046 0.789±0.0419 0.776±0.0458 0.731±0.0542
Depth 32 0.824±0.0329 0.832±0.0302 0.816±0.0342 0.781±0.04
Depth 64 0.815±0.0252 0.814±0.0265 0.804±0.0262 0.768±0.0306
as model 1, even with an extra classification task. The poor reconstruction performance of
model 3 may result from the trade-off between image reconstruction and classification, and
the limited number of labeled images.
4.4.2 Improved Classification Performance by Semi-Supervised Learning with Unlabeled
Images
The classification performance of three models is shown in Figure 4.5 and Table 4.4. Based
on Table 4.4, the performance of model 2 is inferior compared to the best baseline model
(LP). However, model 3 and model 4 consistently achieve better performance than the
baseline models at all network depths, likely resulting from utilizing the reconstruction
loss for regularizing the network. Thus, when trained with the same amount of labeled
data, only model 2 suffers from underfitting. Model 3 and model 4 achieve similar pre-
diction performance, where model 4 at depth 32 achieves the best average performance
(0.824/pm0.0329). We have also performed the pair-wise two-sample t-test for all models’
prediction performance in Table 4.4. Model 3 and model 4 significantly outperform model
2. However, no significant difference has been identified between model 3 and model 4.
In Figure 4.5, we visualized the significance levels between models 2, 3, and 4 at the same
network depth.
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Figure 4.5: Boxplot of the classification performance of various models and depths. A. The
classification performance of three models using depth 16; B. The performance of three
models using depth 32; C. The performance of three models using depth of 64. Model 3
and model 4 (CAESNet) achieve similar prediction performance and consistently outper-
forms model 2. Model 4 (CAESNet) at depth 32 achieves the best average performance
(0.824±0.0329).
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Figure 4.6: Confusion matrices of various models and depths. Each confusion matrix is
color-coded as a heatmap for visualization purpose. The model 3 and model 4 (CAESNet)
consistently achieves better performance compared to the model 2 at all network depths.
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The confusion matrices of three models with various depths are shown in Figure 4.6.
An ideal classification should achieve the diagonal pattern in the confusion matrix. Model
3 and model 4 concentrate more on the diagonal cells than model 2, which is consistent
with their overall performance. However, both model 3 and model 4 makes a relatively
poor classification for Gastric Cardia (GasCard), Low-Grade Dysplasia (LowG), and High-
Grade Dysplasia (HighG). These three classes are tended to be misclassified as Intestinal
Metaplasia (IntMet). We suspect the limited numbers of samples could cause this misclas-
sification for GasCard, LowG, and HighG, where we only have 29, 23, and 4 samples out
of the 429 labeled images, respectively. On the contrary, we have 153 IntMet samples,
which might dominate the classification decisions.
4.4.3 Fluctuated Performance with the Number of Unlabeled Images
After confirming that utilizing unlabeled images to help the regularization of the encoder
can improve the prediction performance, we want to investigate the influence of the number
of unlabeled images utilized for the model training. With the 2,826 unlabeled images, we
feed the model in an accumulative fashion. For the ratio increasing from 0 to 1.0 with a
step size of 0.1, we always use the first proportions of the unlabeled images. For example,
when the ratio equals 0.1, we use the first 10% of unlabeled images; when the ratio equals
0.2, we use the same first 10% of unlabeled images plus the subsequent 10% of unlabeled
images. There are fluctuations in the prediction performance along with the number of
unlabeled images applied. We have also investigated the influence of data augmentation
on classification performance using model 2, where similar performance fluctuations have
been observed.
4.5 Conclusion and discussion
In this study, we developed CAESNet, a CAE-based semi-supervised learning framework
for the multi-class classification of endomicroscopic images. We conclude that the stacked
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CAE is an effective deep learning method to extract informative features from the eCLE
images based on the extensive experiments. The CAE network allows us to add a regular-
ization for the classification loss and allows us to utilize the unlabeled images to optimize
the encoder in a semi-supervised learning fashion.
When utilizing a different number of unlabeled images, the performance does not fol-
low a monotonic increasing pattern but fluctuates as the number of unlabeled images in-
creased. There are multiple potential explanations. First, the results could be caused by
the training configurations where we apply the same hyperparameters for experiments with
different numbers of unlabeled images. To solve this issue, we need to search optimized
configurations for each model and dataset. Second, the performance may be related to the
quality and underlined labels of the unlabeled images. If the unlabeled images are less
relevant to the labeled images, we may experience an adverse effect when utilizing these
unrelated unlabeled images. We also suspect that if most unlabeled images are from a
specific class, they may preoccupy the autoencoder and make it overfit images from that
class. One possible way to solve this problem is to introduce another coefficient to balance
reconstruction loss and classification loss. When we have a larger number of unlabeled
images, the reconstruction loss typically drops much faster than classification loss. Thus,
we can assign larger weights to classification loss so that we can balance the training of
image classification and image reconstruction.
There are multiple future directions for our semi-supervised model. One future direc-
tion is to improve the unsupervised feature representation by applying adversarial autoen-
coders (AAE). AAE is a probabilistic autoencoder by matching the aggregated posterior
of the hidden code vector of the autoencoder with an arbitrary prior distribution [219].
As a result, the encoder tends to generate more meaningful hidden codes. Currently, we
only use the unlabeled data to improve the unsupervised feature representation with sim-
ple handcrafted data augmentation. With the AAE framework, we can additionally auto-
augment the labeled images from a few labeled images and the unlabeled images [220].
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In this method, we learn a generator for sequences of incremental, black-box transforma-
tion functions (TFs) from the unlabeled images and then apply the learned TF generator
to the labeled images for augmentation of realistic labeled images. This advanced auto-
augmentation for labeled images should be able to improve the classification performance.
Another direction is introducing interpretation for the deep model to enable clinical
translation. By introducing techniques like the attention to visualize the model, we want to
identify the features that contribute most to the correct classification. This process can, in
turn, serve as a parameter tuning or diagnosis step for the model. By examining whether
the neural network is truly picking up the disease-relevant structures for the prediction, we
can differentiate models fitting the data noise from the truly effective models.
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CHAPTER 5
WEAKLY-SUPERVISED LEARNING FOR HISTOPATHOLOGICAL IMAGING
INFORMATICS
5.1 Introduction
Whole-slide imaging (WSI) generates digital slides by scanning conventional glass slides,
which enables the computer-aided diagnosis (CAD) for pathological images and the inte-
gration of digital pathology with high-dimensional genomics features [221]. The virtual
slide with a resolution almost at the optical resolution limits can be generated in sixty sec-
onds for an entire glass slide [221]. The resulting virtual slides consist of digital images of
histological sections over a complete range of standard magnifications. Extensive valida-
tions by the College of American Pathologists Pathology have demonstrated WSI’s effec-
tiveness for diagnostic interpretation [222]. Manual examination of slides and diagnosis by
pathologists can be subjective and time-consuming because of the large fields-of-view to
be reviewed. With the adoption of WSI systems in clinical settings, researchers have built
numerous CAD systems for various clinical endpoints. The development of WSI and the
corresponding computational algorithms forms two major components of digital pathology,
which has paved the way towards precision medicine. Due to the large size of image data
contained in a virtual slide, it is impractical to process the entire digital image of a slide as
a whole. Most CAD systems first select the region of interest (ROI) using low-resolution
thumbnails and then tile the image within ROIs into small image patches at the highest
magnification level. After the tiling process, the image patches are processed with feature
extraction, feature selection, and predictive modeling for conventional digital image pro-
cessing pipelines. With the huge success of deep learning in natural images, models like
deep convolutional networks (ConvNets) have also been applied to these image patches for
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efficient feature representation. The features generated by ConvNets are then fed into extra
networks for segmentation and classification. Recent works have demonstrated promising
results for applying deep learning to WSI [40, 42].
However, current CAD models typically process the image patches independently with-
out considering each patch’s geographical relationships. This paradigm results in two major
drawbacks. First, the image patches are processed without the support from neighboring
image patches, which may contain useful context information. For example, specific struc-
tures may be partially cropped in a specific image patch and reduce the power of feature
representation. Second, only the finest images at the highest magnification are used for fea-
ture extraction, while the coarser images at lower magnifications are discarded completely.
These coarser images also carry useful information and should have been utilized for the
feature representation. To address these drawbacks of current CAD models for pathologi-
cal images, we propose exploiting each image patch’s context information with multi-scale
ConvNets. Besides the basic image patch tiled from the finest resolution, we also extract
image patches from two lower resolutions at the same geographic center to provide context
information (Fig. 5.1). These two extra image patches are captured from the WSI image
pyramid’s coarser levels and thus have larger Field of Views (FOVs) compared with the
original image patches. We build three ConvNets for three concentrical image patches
and then combine the extracted features for the final classification of the primary image
patch. We have applied our multi-scale ConvNets to a benchmark breast cancer dataset.
Extensive experiments have demonstrated that our multi-scale ConvNets can significantly
improve the classification performance of breast cancer.
5.2 Related Works
5.2.1 Computer-aided diagnosis for WSI
The development of CAD systems for digital pathology has become one of the fastest-





Figure 5.1: Visualization of concentric images with different FOVs. From (a) to (c), the
FOV is getting smaller and smaller, with more zoomed in view of the same image patch.
122
consists of four major components: 1) image quality control, 2) feature extraction at the
pixel, object, and semantic levels, 3) predictive modeling using imaging features, and 4)
model visualization for interactive discovery [35].
Image quality control is an essential step for digital pathology because of the hetero-
geneities of WSIs collected between different clinical sites with various platforms and slide
preparation protocols, which is the so-called batch effect. On the other hand, the WSI may
also have artifacts, including tissue folds, blurred regions, pen marks, and shadows. The
batch effects and image artifacts have unpredictable effects on image segmentation, classi-
fication, and other quantitative image analysis tasks. Researchers have developed multiple
techniques, including color normalization, scale normalization, and blur detection, to elim-
inate or correct the batch-effect and image artifacts of WSIs.
Feature extraction is another essential step to represent the WSI data quantitatively.
Conventional digital imaging processing techniques extract features from pathological im-
ages at pixel and object levels to capture the morphological properties [36]. Pixel-level
feature extraction identifies the properties of color and texture for all image pixels. Color
features are typically expressed with the color spread, prominence, and co-occurrence us-
ing statistics and frequencies of color histograms in different color spaces. Texture features
quantify image sharpness, contrast, changes in intensity, and discontinuities or edges by
measuring properties from gray-level intensity profiles. Object-level feature extraction re-
quires the segmentation of cellular structures and captures the shape, texture, and spatial
distribution of cellular structures in a WSI. Besides the features extracted from WSI, re-
searchers also proposed to integrate the pathological features with clinical features and
genomic features for improved diagnosis [37].
However, the conventional feature extraction relies heavily on hand-crafted features,
limiting the generalizability of the features. With deep learning development, the human-
designed feature extraction has been replaced by feature representation with deep neural
networks. For imaging data, the most popular feature representation network is the convo-
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lutional neural network (ConvNets). Deep ConvNets can learn efficient feature represen-
tation from a large amount of training data. By combining ConvNets with fully connected
(FC) layers and a softmax layer for classification, the deep networks can be trained end-to-
end and thus can learn both feature representation and classification from the training data.
With the success of deep learning in natural images, deep neural networks like ConvNets
have been applied to medical images including MRI (brain tumor [38]), CT (lung nodule
[39]), and WSI (breast cancer [40], lung cancer [41], glioma [42], heart rejection [43] etc.).
5.2.2 Image pyramids and multi-scale models for natural images
The image pyramids applied in object recognition inspire our multi-scale ConvNets for
WSI. Image pyramids consist of multi-scale representations of the same image. Feature
pyramids built upon image pyramids are among the most standard solutions for object
recognition at various scales in computer vision. The object’s scale change is offset by its
level within the pyramid so that the objects can be recognized in a scale-invariant fashion.
By scanning a trained model over both positions and pyramid levels, objects across a large
range of scales can be robustly detected. Before the deep learning era, dense sampling on
image pyramids and hand-crafted features are critical for accurate object detection. With
the success of deep learning for natural images, the hand-crafted feature extraction step has
been replaced by the powerful feature representation using deep ConvNets. Although Con-
vNets are much more robust to scale variances than hand-crafted features, image pyramids
are utilized to ensure the most accurate performance. For example, multiple top entries
in the ImageNet [223] and COCO [224] detection challenges exploit multi-scale inference
with image pyramids.
Besides the direct application of image pyramids for multi-scale inference, recent works
have also utilized the built-in feature hierarchy of deep ConvNets for multi-scale feature
representations. For example, the feature pyramid network (FPN) uses the pyramid shape
of a ConvNet’s feature hierarchy. It builds semantically strong multi-scale representations
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with the bottom-up pathway, top-down pathway, and lateral connections [225]. The FPN
gets rid of image pyramids and creates in-network feature pyramids, which significantly
reduces the speed and memory without sacrificing the multi-scale representation power.
Multiple works, including Mask R-CNN [226], has utilized the FPN framework to achieve
improved performance.
One major difference between our work and the multi-scale object detection is that we
aim to use the built-in image pyramids of WSI and improve the prediction performance
with the support of context information. Thus, we improve the current model by enlarging
the FOVs using images of coarser levels on the WSI image pyramids.
5.2.3 Multi-scale features for medical images
Xu et al. have applied multi-scale context-aware networks for colorectal liver metastases
[227]. They utilized the context information from low magnification levels by concate-
nating the feature maps generated by deep convolutional neural networks at early and late
stages. The combined features improved the performance for image segmentation and clas-
sification tasks.
5.3 Multi-scale convolutional networks
5.3.1 Late Fusion
One intuitive way to integrate images from different scales is to combine the hidden feature
vectors extracted from the three concentric images. Since the integration happens before
the last FC layer, we call this family of methods as of late fusion (Fig. 5.2). We first
use the five layers of ConvNets and two FC layers to extract features from input images,
respectively. After the five layers of convolution, each image is represented with a feature
map with size 256× 6× 6. We then flatten the feature maps and get a vector with a length
of 4, 096 for each image after the two FC layers. Finally, we combine the feature vectors
before feeding the last classification layer by concatenating or taking the average. The
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Figure 5.2: Visualization of multi-scale patch integration by late fusion. The information
extracted from each scale is not combined until feeding into classification layer. The feature
vectors represented from each scale of concentric image patches are integrated by either
concatenation or taking average. The combined feature vectors are then fed into last FC
layer for classification.
combined feature vectors then go through another FC layer for classification.
5.3.2 Early Fusion
Another way to integrate these multi-scale images is to combine the feature maps at a
relatively early stage within the five layers of ConvNets. We call these methods early
fusion. Based on the methods we use to fuse the feature maps, we can further classify them
into full concatenation and partial fusion.
Full concatenation directly concatenates the feature maps of different concentric images
(Fig. 5.3). Since the images are scaled to the same dimension (3× 224× 224) and parsed
through ConvNets of the same structure, the feature maps also have the same dimension.
We can directly concatenate these feature maps along the depth dimension and then feed the
combined feature maps to the rest of the networks. Since the concatenation will increase
the depth by three times, the following ConvnNet is modified correspondingly. To simplify
the model, we share all network parameters for three levels of images.
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Figure 5.3: Visualization of multi-scale patch integration by early fusion and full concate-
nation. The feature maps generated by convolutional neural networks are fully concate-
nated. We have tried to concatenate the feature maps at the third and fourth ConvNet layers
respectively.
Figure 5.4: Visualization of multi-scale patch integration early partial fusion. We fuse the
feature maps of multi-scale images sequentially. The image with smaller field of view
is processed with two ConvNet layers and then fused with the image processed with one
ConvNet layer.
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(a) Partially merge the feature maps by 1× 1 convolution and element wise average.
(b) The illustration of partially overlapped feature maps based on field of views.
Figure 5.5: Details of partial fusion methods.
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Table 5.1: Experiment Results for Multi-Scale ConvNets




+ - - - - 35.50± 4.04 %
+ - - - + 68.75± 3.20%
- + - - - 29.00± 7.35%
- + - - + 78.75± 2.99%
- - + - - 30.75± 9.60%
- - + - + 74.50± 5.57%
Late Fusion
+ + + Z concat + 81.50± 2.38%
+ + + Z mean + 79.75± 1.89%
Early Fusion
+ + + Conv3 concat + 80.50± 3.41%
+ + + Conv4 concat + 79.25± 4.27%
+ + + Partial fusion + 72.00± 4.08%
Partial fusion aims to consider the various FOVs when integrate the multi-scale feature
maps (Fig. 5.4). The feature maps are merged sequentially. One image with smaller FOVs
is firstly passed through two ConvNets to get smaller feature maps. While the other image
with larger FOVs is passed through one ConvNets and get larger feature maps. The depth
of smaller feature maps is reduced to match that of larger feature maps by 1×1 convolution
(Fig. 5.5a). Then they are partially merged by aligning them at the center and take means of
the overlapped elements (Fig. 5.5b). After two partial fusions to combine the three multi-
scale images, the integrated feature maps are processed by the remaining three layers of
ConvNets and three FC layers for classification.
5.4 Experiments
5.4.1 Datasets
The dataset we use in this study is Part A - microscopy images from ICIAR 2018 Grand
Challenge on Breast Cancer Histology images [229]. The dataset contains 400 microscopy
images, labeled as one of the following classes: normal, benign, in situ carcinoma and
invasive carcinoma. Each class contains 100 images. The size of each image is 2048×1536
pixels. Two medical experts performed the labeling of images, and label disagreements
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Figure 5.6: Visualization of important regions for predictions in different scales of an ex-
ample image using Grad-CAM [228].
have been excluded from the dataset.
5.4.2 Data Normalization
Because of the variations in preparing each tissue sample and scanning for microscopic
examination, we found significant visual differences in the histology images. To prevent
this artifact from affecting our classification results, we use a color normalization method
based on non-negative matrix factorization (NMF) [230]. Specifically, the method calcu-
lates stain color bases and stain densities in an unsupervised manner for a given image.
We rebase the color distribution of each image by multiplying reference color bases and
normalized stain densities. Our study uses Image b027 as the reference image.
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5.4.3 Data Augmentation
Given that we have only limited image samples compared to typical DL applications, we
augment our data to increase variations of the data and to reduce over-fitting when training
our models. Specifically, we rotate the original image and crop it to a desired size (either
256× 256, 512× 512, or 1024× 1024 pixels) (Fig. 5.1). We make sure that each cropped
image will not contain more than 30% of the white background. We resize each cropped
image to 224×224 pixels to fit the input size of AlexNet, the backbone network architecture
we use.
5.4.4 Settings of hyperparameters
We use four-fold cross-validation and set 300 images as the training set and the remaining
100 images as the test set. Both the training and test sets have an even distribution of four
class labels. During training, the batch size is set to 60. We use stochastic gradient descent
(SGD) and set the momentum to 0.9 for optimization. We set a relatively large learning rate
of 0.01 when we do not use ImageNet-pretrained parameters and a relatively small learning
rate of 0.0002 when we use ImageNet-pretrained parameters. We record the best accuracy
for the test set during 200 training iterations for each fold and report the mean and standard
deviation best accuracy for all folds.
5.5 Results
We list the prediction accuracy in (Table 5.1). Below we talk about our major findings.
5.5.1 ImageNet Pretraining
We found out that using ImageNet-pretrained parameters to initialize our model signifi-
cantly improved the prediction accuracy. In Table 5.1, the increase is 33.25%, 49.75%, and
43.75% under the FOV as 256× 256, 512× 512, and 1024× 1024, respectively. ImageNet
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is a large image database that contains 1.28 million images that belong to 1, 000 classes.
The classes cover a wide variety of common objects such as hen and cat. Although general
image classification is very different from pathological image classification, the large and
comprehensive ImageNet data set enables the convolutional filters of AlexNet to capture
the heterogeneous and basic visual components in the world. Therefore, ImageNet pre-
trained parameters set the stage for training DL models for pathology image classification,
given the limited number of pathology images in the Challenge.
5.5.2 Field of View
From Table 5.1, we see that choices of FOV affect prediction accuracy. Specifically, when
we set a small FOV (256×256 pixels), the prediction accuracy is lowest with ImageNet pre-
training among three sizes of FOV. With ImageNet pretraining, the medium FOV (512×512
pixels) achieves the best accuracy 78.75% among single-scale inputs. To better understand
the effect of FOV, we visualize an example image in three scales and highlight important
regions for AlexNet prediction with Grad-CAM [228]. We argue that although large FOV
includes the most context information for classification, they lose the most details when
we resize the input to fit the specified input size of AlexNet (224 × 224). On the other
hand, small FOVs (256 × 256) are most likely to miss distinctive regions for identifying
cancers. The medium FOV (512 × 512) maintains a good balance between context and
detailed information (Fig 5.6).
5.5.3 Multi-scale Input
Table 5.1 shows that multi-scale input increases prediction accuracy up to 81.5% when we
combine the features at a late stage by concatenating feature vectors before the last fully
connected layers and share the parameters of AlexNet backbone for each scale of input.
The difference in accuracy between the two late fusion methods we use, concatenation
and averaging of the feature vector before the last fully connected layers, is minor (81.5%
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and 79.75%). The difference between late fusion and the two early fusion methods by
concatenating feature maps at Conv layer 3 and Conv layer 2 is also small (within 1.25%).
However, partial fusion accuracy is only 72%, which is less than that of single scale input
at FOV of 512 and 1024. We reason that partial fusion’s inferior performance may be
caused by the interruption of the original AlexNet structures. With a limited number of
training data, the original AlexNet structure with pertained parameters contributes most to
the classification performance.
5.6 Conclusions and Discussions
In this study, we have built multi-scale ConvNets for late fusion and early fusion of the
WSI image pyramids to improve breast cancer classification. Based on the extensive ab-
lation experiments, we found that the late fusion method by taking the average of feature
vectors and sharing AlexNet pre-trained parameters reaches the highest accuracy (80%).
The proposed method beats the other methods, including late fusion by concatenation,
early fusion by concatenation, and early partial fusion. We conclude that 1) utilizing the
AlexNet pre-trained parameters, 2) multi-scale image pyramid inputs, and 3) sharing net-
work parameters contribute to better classification performance. We hope the work can




This dissertation has developed methods to enable precision medicine by integrating multi-
modal biomedical data and integrating unlabeled or weakly labeled biomedical data. The
proposed methods have been validated on multiple biomedical applications, including pre-
dicting Alzheimer’s disease, multi-omics based breast cancer survival analysis, diagnosing
Barrett’s esophagus endomicroscopic images, and predicting breast cancer pathological
images.
For independent multi-modal data, we utilize the complementary principle to integrate
independent modalities by concatenating hidden features learned with independent feature
representation. We have applied to the prediction of Alzheimer’s Disease by integrating
EHRs, SNPs, and MR images [116].
For dependent multi-modal data (e.g., multi-omics), we utilize the consensus princi-
ple to integrate dependent modalities by modeling the complex interactions implicitly and
learning a modality-invariant feature representation. For the application of the proposed
methods to multi-omics data, we first investigated RNA-seq pipeline selection for gene ex-
pression estimation [119]. We then applied cross-modality translation network [176] and
divergence-based consensus network [183] to breast cancer multi-omics data.
We have developed an autoencoder-based semi-supervised learning framework for the
generalized biomedical data integration for unlabeled data. We have applied the proposed
network to improve Barrett’s esophagus classification by integrating unlabeled endomicro-
scopic images [196]. We have also developed a multi-scale convolutional network to inte-
grate the context-aware features for the image pyramids of whole-slide images and applied
to breast cancer classification for improved performance [231].
In conclusion, we have developed multiple models to integrate multi-modal biomedical
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data. By validating the proposed models to multiple biomedical applications, we have
demonstrated the effectiveness and potential of multi-modal integration for biomedical
data, which is essential towards precision medicine.
However, several limitations have been identified and can be improved to achieve more
robust performance. The first limitation of the dissertation work is the feature extraction
and selection for multi-omics data. With the “curse of dimensionality” in multi-omics data
(i.e., small sample size vs. huge feature dimensions), feature selection or dimension re-
duction is essential for the success of machine learning techniques. In the dissertation,
we have applied PCA or high-variance filtering to the multi-omics data for dimension re-
duction, which are two simple and unsupervised dimension reduction techniques. As a
separate preprocessing step, the feature selection is performed on each data modality inde-
pendently and separated from the downstream training. One future direction is to improve
the feature extraction/selection for multi-omics data by end-to-end feature selection and
predictive modeling.
The second limitation is the proposed multi-modality data integration approach. In
this dissertation, we utilize consensus or complementary principles to integrated different
multi-modal biomedical data. A promising direction would be to improve the data integra-
tion methods and explore strategies beyond consensus and complementary principle. One
promising future direction could be causal inferences, in which we can identify causal rela-
tionships among modalities using multi-omics data. The causal inference among modalities
can potentially facilitate knowledge mining and biological validation.
The third limitation of the methods developed in this dissertation is the lack of model
interpretation. As a purely data-driven approach, the deep neural networks worked as a
black box, and the model behaviors are hard to interpret or diagnose. However, model
transparency is essential to build trust for caregivers and patients. The interpretation can
also facilitate model validation, which can improve the model reproducibility and general-
izability. Thus, one essential future direction is to enable model interpretation for the deep
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learning-based multi-omics integration models and improve the model transparency.
The last limitation is the quality control of multi-modal biomedical data. Although ba-
sic quality controls have been applied to the multi-modal data utilized in this dissertation,
a more robust and sophisticated quality control can significantly improve the stability of
the proposed pipelines. The primary direction is to improve the modality-specific qual-
ity control (e.g., missing values for EHR data; color variations, motion artifacts, blur for
medical images; sample contaminations and sequencing variations for multi-omics data).
Another quality control direction is to mitigate missing modality issues by methods such
as imputation, which can significantly increase the amount of training data.
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man, T. J. Hubbard, J. Harrow, R. Guigó, and P. Bertone, “Systematic evaluation of
154
spliced alignment programs for RNA-seq data,” Nature Methods, vol. 10, no. 12,
pp. 1185–1191, 12 Dec. 2013.
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